{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T05:50:00Z","timestamp":1794376200597,"version":"4.9.0"},"reference-count":309,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32325003"],"award-info":[{"award-number":["32325003"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2024M762020"],"award-info":[{"award-number":["2024M762020"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Postdoctoral Fellowship Program of CPSF","award":["GZB20240442"],"award-info":[{"award-number":["GZB20240442"]}]},{"name":"Shanghai Sailing Program","award":["24YF2726900"],"award-info":[{"award-number":["24YF2726900"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biomed"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Poly\u00a0(ADP-ribose) polymerases (PARPs) are a diverse family of enzymes that regulate genome stability, cell death, and stress responses through ADP-ribosylation. Among them, PARP1, PARP2, and PARP3 are central to cellular DNA repair, while tankyrases, and their isoforms, contribute to telomere maintenance, transcriptional regulation, immune signaling, and metabolism. Dysregulated PARP activity drives genomic instability, apoptosis, parthanatos, and tumor microenvironment remodeling, thereby linking PARPs to oncogenesis, immune escape, and therapy resistance. Clinically, PARP inhibitors (PARPi), such as olaparib, niraparib, rucaparib, and talazoparib, exploit synthetic lethality in homologous recombination\u2013deficient tumors and are increasingly applied in ovarian, breast, prostate, and pancreatic cancers. Beyond oncology, preclinical studies demonstrate antiviral efficacy of PARPi\u00a0against hepatitis B virus, human immunodeficiency virus, and coronaviruses, and also therapeutic potential in neurodegeneration, cardiovascular disease, fibrosis, and metabolic disorders. However, PARPi resistance arises through restoration of DNA repair, replication fork protection, epigenetic changes, and drug-target dynamics, while adverse events\u2014including hematologic toxicity, gastrointestinal disturbance, and organ-specific effects\u2014limit a broader use. Next-generation PARPi with improved isoform selectivity, PROteolysis-TArgeting Chimera (PROTAC) degraders, and rational combinations with ATR\/CHK1 inhibitors, immune checkpoint blockade, or epigenetic modulators offer strategies to enhance efficacy and overcome resistance. Emerging biomarker-driven approaches, including liquid biopsies and functional assays, may further personalize therapy. By integrating canonical DNA repair roles with non-canonical signaling and host\u2013virus interactions, PARPs represent pivotal regulators. Similarly, the versatile therapeutics of PARPi have implications that extend beyond oncology into a broader and diverse range of other human diseases.<\/jats:p>","DOI":"10.1186\/s43556-025-00385-1","type":"journal-article","created":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T12:53:53Z","timestamp":1767012833000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["PARPs and PARP inhibitors: molecular mechanisms and clinical applications"],"prefix":"10.1186","volume":"6","author":[{"given":"Fei","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuyi","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Carr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8717-2942","authenticated-orcid":false,"given":"Weifeng","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,29]]},"reference":[{"key":"385_CR1","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/0006-291x(63)90024-x","volume":"11","author":"P Chambon","year":"1963","unstructured":"Chambon P, Weill JD, Mandel P. Nicotinamide mononucleotide activation of a new DNA-dependent polyadenylic acid synthesizing nuclear enzyme. Biochem Biophys Res Commun. 1963;11:39\u201343. https:\/\/doi.org\/10.1016\/0006-291x(63)90024-x.","journal-title":"Biochem Biophys Res Commun"},{"key":"385_CR2","doi-asserted-by":"publisher","first-page":"5188","DOI":"10.1021\/bi00291a019","volume":"22","author":"JL Sims","year":"1983","unstructured":"Sims JL, Berger SJ, Berger NA. Poly(ADP-ribose) polymerase inhibitors preserve oxidized nicotinamide adenine dinucleotide and adenosine 5\u2019-triphosphate pools in DNA-damaged cells: mechanism of stimulation of unscheduled DNA synthesis. Biochemistry. 1983;22:5188\u201394. https:\/\/doi.org\/10.1021\/bi00291a019.","journal-title":"Biochemistry"},{"key":"385_CR3","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/nsmb.2335","volume":"19","author":"AAE Ali","year":"2012","unstructured":"Ali AAE, Timinszky G, Arribas-Bosacoma R, Kozlowski M, Hassa PO, Hassler M, et al. The zinc-finger domains of PARP1 cooperate to recognize DNA strand breaks. Nat Struct Mol Biol. 2012;19:685\u201392. https:\/\/doi.org\/10.1038\/nsmb.2335.","journal-title":"Nat Struct Mol Biol"},{"key":"385_CR4","doi-asserted-by":"publisher","first-page":"15990","DOI":"10.1016\/S0021-9258(18)47687-9","volume":"262","author":"T Kurosaki","year":"1987","unstructured":"Kurosaki T, Ushiro H, Mitsuuchi Y, Suzuki S, Matsuda M, Matsuda Y, et al. Primary structure of human poly(ADP-ribose) synthetase as deduced from cDNA sequence. J Biol Chem. 1987;262:15990\u20137.","journal-title":"J Biol Chem"},{"key":"385_CR5","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1038\/s41573-020-0076-6","volume":"19","author":"NJ Curtin","year":"2020","unstructured":"Curtin NJ, Szabo C. Poly(ADP-ribose) polymerase inhibition: past, present and future. Nat Rev Drug Discov. 2020;19:711\u201336. https:\/\/doi.org\/10.1038\/s41573-020-0076-6.","journal-title":"Nat Rev Drug Discov"},{"key":"385_CR6","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.sbi.2018.11.002","volume":"53","author":"MF Langelier","year":"2018","unstructured":"Langelier MF, Eisemann T, Riccio AA, Pascal JM. PARP family enzymes: regulation and catalysis of the poly(ADP-ribose) posttranslational modification. Curr Opin Struct Biol. 2018;53:187\u201398. https:\/\/doi.org\/10.1016\/j.sbi.2018.11.002.","journal-title":"Curr Opin Struct Biol"},{"key":"385_CR7","doi-asserted-by":"publisher","first-page":"e121291","DOI":"10.1172\/jci.insight.121291","volume":"4","author":"Q Shou","year":"2019","unstructured":"Shou Q, Fu H, Huang X, Yang Y. PARP-1 controls NK cell recruitment to the site of viral infection. JCI Insight. 2019;4:e121291. https:\/\/doi.org\/10.1172\/jci.insight.121291.","journal-title":"JCI Insight"},{"key":"385_CR8","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.tibs.2009.12.003","volume":"35","author":"MO Hottiger","year":"2010","unstructured":"Hottiger MO, Hassa PO, Luscher B, Schuler H, Koch-Nolte F. Toward a unified nomenclature for mammalian ADP-ribosyltransferases. Trends Biochem Sci. 2010;35:208\u201319. https:\/\/doi.org\/10.1016\/j.tibs.2009.12.003.","journal-title":"Trends Biochem Sci"},{"key":"385_CR9","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1126\/science.aam7344","volume":"355","author":"CJ Lord","year":"2017","unstructured":"Lord CJ, Ashworth A. PARP inhibitors: synthetic lethality in the clinic. Science. 2017;355:1152\u20138. https:\/\/doi.org\/10.1126\/science.aam7344.","journal-title":"Science"},{"key":"385_CR10","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1038\/nature03443","volume":"434","author":"HE Bryant","year":"2005","unstructured":"Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005;434:913\u20137. https:\/\/doi.org\/10.1038\/nature03443.","journal-title":"Nature"},{"key":"385_CR11","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/nature03445","volume":"434","author":"H Farmer","year":"2005","unstructured":"Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature. 2005;434:917\u201321. https:\/\/doi.org\/10.1038\/nature03445.","journal-title":"Nature"},{"key":"385_CR12","doi-asserted-by":"publisher","first-page":"5605","DOI":"10.1158\/0008-5472.CAN-21-3201","volume":"81","author":"DB Krastev","year":"2021","unstructured":"Krastev DB, Wicks AJ, Lord CJ. PARP inhibitors \u2013 trapped in a toxic love affair. Cancer Res. 2021;81:5605\u20137. https:\/\/doi.org\/10.1158\/0008-5472.CAN-21-3201.","journal-title":"Cancer Res"},{"key":"385_CR13","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1126\/science.1216338","volume":"336","author":"MF Langelier","year":"2012","unstructured":"Langelier MF, Planck JL, Roy S, Pascal JM. Structural basis for DNA damage-dependent poly(ADP-ribosyl)ation by human PARP-1. Science. 2012;336:728\u201332. https:\/\/doi.org\/10.1126\/science.1216338.","journal-title":"Science"},{"key":"385_CR14","doi-asserted-by":"publisher","unstructured":"Eustermann S, Wu WF, Langelier MF, Yang JC, Easton LE, Riccio AA, et al. Structural Basis of Detection and Signaling of DNA Single-Strand Breaks by Human PARP-1. Mol Cell. 2015; 60:742\u2013754.https:\/\/doi.org\/10.1016\/j.molcel.2015.10.032.","DOI":"10.1016\/j.molcel.2015.10.032"},{"key":"385_CR15","doi-asserted-by":"publisher","unstructured":"Kim MK. Novel insight into the function of tankyrase. Oncol Lett. 2018; 16:6895\u20136902.https:\/\/doi.org\/10.3892\/ol.2018.9551.","DOI":"10.3892\/ol.2018.9551"},{"key":"385_CR16","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1038\/ncomms3240","volume":"4","author":"S Vyas","year":"2013","unstructured":"Vyas S, Chesarone-Cataldo M, Todorova T, Huang YH, Chang P. A systematic analysis of the PARP protein family identifies new functions critical for cell physiology. Nat Commun. 2013;4:2240. https:\/\/doi.org\/10.1038\/ncomms3240.","journal-title":"Nat Commun"},{"key":"385_CR17","doi-asserted-by":"publisher","unstructured":"Lei P, Li W, Luo J, Xu N, Wang Y, Xie D, et al. PARP (Poly ADP-ribose Polymerase) Family in Health and Disease. MedComm (2020). 2025; 6:e70314.https:\/\/doi.org\/10.1002\/mco2.70314.","DOI":"10.1002\/mco2.70314"},{"key":"385_CR18","doi-asserted-by":"publisher","unstructured":"Bohi F, Hottiger MO. Expanding the Perspective on PARP1 and Its Inhibitors in Cancer Therapy: From DNA Damage Repair to Immunomodulation. Biomedicines. 2024; 12.https:\/\/doi.org\/10.3390\/biomedicines12071617.","DOI":"10.3390\/biomedicines12071617"},{"key":"385_CR19","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1007\/s12609-025-00582-5","volume":"17","author":"A Ray","year":"2025","unstructured":"Ray A, Opyrchal M. Targeting PARP1: a promising approach for next-generation poly (ADP-ribose) polymerase inhibitors. Curr Breast Cancer Rep. 2025;17:22. https:\/\/doi.org\/10.1007\/s12609-025-00582-5.","journal-title":"Curr Breast Cancer Rep"},{"key":"385_CR20","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1038\/s41419-024-07277-2","volume":"15","author":"L Chen","year":"2024","unstructured":"Chen L, Zou Y, Sun R, Huang M, Zhu X, Tang X, et al. Minimizing DNA trapping while maintaining activity inhibition via selective PARP1 degrader. Cell Death Dis. 2024;15:898. https:\/\/doi.org\/10.1038\/s41419-024-07277-2.","journal-title":"Cell Death Dis"},{"key":"385_CR21","doi-asserted-by":"publisher","first-page":"106952","DOI":"10.1016\/j.bioorg.2023.106952","volume":"142","author":"Y Wu","year":"2024","unstructured":"Wu Y, Wu M, Zheng X, Yu H, Mao X, Jin Y, et al. Discovery of a potent and selective PARP1 degrader promoting cell cycle arrest via intercepting CDC25C-CDK1 axis for treating triple-negative breast cancer. Bioorg Chem. 2024;142:106952. https:\/\/doi.org\/10.1016\/j.bioorg.2023.106952.","journal-title":"Bioorg Chem"},{"key":"385_CR22","doi-asserted-by":"publisher","first-page":"569","DOI":"10.3389\/fimmu.2016.00569","volume":"7","author":"Y Li","year":"2016","unstructured":"Li Y, Wu Y, Zheng X, Cong J, Liu Y, Li J, et al. Cytoplasm-translocated Ku70\/80 complex sensing of HBV DNA induces hepatitis-associated chemokine secretion. Front Immunol. 2016;7:569. https:\/\/doi.org\/10.3389\/fimmu.2016.00569.","journal-title":"Front Immunol"},{"issue":"13","key":"385_CR23","doi-asserted-by":"publisher","first-page":"3741","DOI":"10.1016\/j.celrep.2018.05.084","volume":"23","author":"D Yu","year":"2018","unstructured":"Yu D, Liu R, Yang G, Zhou Q. The PARP1-Siah1 axis controls HIV-1 transcription and expression of Siah1 substrates. Cell Rep. 2018;23(13):3741\u20139. https:\/\/doi.org\/10.1016\/j.celrep.2018.05.084.","journal-title":"Cell Rep"},{"key":"385_CR24","doi-asserted-by":"publisher","unstructured":"Xia C, Wolf JJ, Sun C, Xu M, Studstill CJ, Chen J, et al. PARP1 Enhances Influenza A Virus Propagation by Facilitating Degradation of Host Type I Interferon Receptor. J Virol. 2020; 94.https:\/\/doi.org\/10.1128\/JVI.01572-19.","DOI":"10.1128\/JVI.01572-19"},{"key":"385_CR25","doi-asserted-by":"publisher","first-page":"4782","DOI":"10.1111\/bph.17305","volume":"181","author":"H Papp","year":"2024","unstructured":"Papp H, Toth E, Bovari-Biri J, Banfai K, Juhasz P, Mahdi M, et al. The PARP inhibitor rucaparib blocks SARS-CoV-2 virus binding to cells and the immune reaction in models of COVID-19. Br J Pharmacol. 2024;181:4782\u2013803. https:\/\/doi.org\/10.1111\/bph.17305.","journal-title":"Br J Pharmacol"},{"key":"385_CR26","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1089\/neu.2013.3194","volume":"31","author":"BA Stoica","year":"2014","unstructured":"Stoica BA, Loane DJ, Zhao Z, Kabadi SV, Hanscom M, Byrnes KR, et al. PARP-1 inhibition attenuates neuronal loss, microglia activation and neurological deficits after traumatic brain injury. J Neurotrauma. 2014;31:758\u201372. https:\/\/doi.org\/10.1089\/neu.2013.3194.","journal-title":"J Neurotrauma"},{"key":"385_CR27","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1124\/jpet.104.076711","volume":"312","author":"T Genovese","year":"2005","unstructured":"Genovese T, Mazzon E, Muia C, Patel NS, Threadgill MD, Bramanti P, et al. Inhibitors of poly(ADP-ribose) polymerase modulate signal transduction pathways and secondary damage in experimental spinal cord trauma. J Pharmacol Exp Ther. 2005;312:449\u201357. https:\/\/doi.org\/10.1124\/jpet.104.076711.","journal-title":"J Pharmacol Exp Ther"},{"key":"385_CR28","doi-asserted-by":"publisher","unstructured":"Wu S, Zeng X, Liu J, Cong K, Lou S, Li Z, et al. Discovery and Optimization of Potent and Highly Selective PARP14 Inhibitors for the Treatment of Atopic Dermatitis. J Med Chem. 2025; 68:9755\u20139776.https:\/\/doi.org\/10.1021\/acs.jmedchem.5c00564.","DOI":"10.1021\/acs.jmedchem.5c00564"},{"key":"385_CR29","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1111\/j.1527-3466.2007.00018.x","volume":"25","author":"P Pacher","year":"2007","unstructured":"Pacher P, Szabo C. Role of poly(ADP-ribose) polymerase 1 (PARP-1) in cardiovascular diseases: the therapeutic potential of PARP inhibitors. Cardiovasc Drug Rev. 2007;25:235\u201360. https:\/\/doi.org\/10.1111\/j.1527-3466.2007.00018.x.","journal-title":"Cardiovasc Drug Rev"},{"key":"385_CR30","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1016\/j.drudis.2020.04.019","volume":"25","author":"PD Rao","year":"2020","unstructured":"Rao PD, Sankrityayan H, Srivastava A, Kulkarni YA, Mulay SR, Gaikwad AB. \u2019PARP\u2019ing fibrosis: repurposing poly (ADP ribose) polymerase (PARP) inhibitors. Drug Discov Today. 2020;25:1253\u201361. https:\/\/doi.org\/10.1016\/j.drudis.2020.04.019.","journal-title":"Drug Discov Today"},{"key":"385_CR31","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/s41597-025-04722-5","volume":"12","author":"J Zheng","year":"2025","unstructured":"Zheng J, Deng Y, Fang C, Xiong S, Zhu X, Wu W, et al. Comprehensive dataset of interactors for the entire PARP family using TurboID proximity labeling. Sci Data. 2025;12:405. https:\/\/doi.org\/10.1038\/s41597-025-04722-5.","journal-title":"Sci Data"},{"key":"385_CR32","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1016\/j.tibs.2021.01.014","volume":"46","author":"N Pandey","year":"2021","unstructured":"Pandey N, Black BE. Rapid detection and signaling of DNA damage by PARP-1. Trends Biochem Sci. 2021;46:744\u201357. https:\/\/doi.org\/10.1016\/j.tibs.2021.01.014.","journal-title":"Trends Biochem Sci"},{"key":"385_CR33","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.dnarep.2018.08.022","volume":"71","author":"JM Pascal","year":"2018","unstructured":"Pascal JM. The comings and goings of PARP-1 in response to DNA damage. DNA Repair (Amst). 2018;71:177\u201382. https:\/\/doi.org\/10.1016\/j.dnarep.2018.08.022.","journal-title":"DNA Repair (Amst)"},{"key":"385_CR34","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/j.molcel.2016.06.019","volume":"63","author":"L Mariotti","year":"2016","unstructured":"Mariotti L, Templeton CM, Ranes M, Paracuellos P, Cronin N, Beuron F, et al. Tankyrase Requires SAM Domain-Dependent Polymerization to Support Wnt-\u03b2-Catenin Signaling. Mol Cell. 2016;63:498\u2013513. https:\/\/doi.org\/10.1016\/j.molcel.2016.06.019.","journal-title":"Mol Cell"},{"key":"385_CR35","doi-asserted-by":"publisher","unstructured":"Du Q, Miao Y, He W, Zheng H. ADP-Ribosylation in Antiviral Innate Immune Response. Pathogens. 2023;12.https:\/\/doi.org\/10.3390\/pathogens12020303.","DOI":"10.3390\/pathogens12020303"},{"key":"385_CR36","doi-asserted-by":"publisher","first-page":"zcad009","DOI":"10.1093\/narcan\/zcad009","volume":"5","author":"A Dhoonmoon","year":"2023","unstructured":"Dhoonmoon A, Nicolae CM. Mono-ADP-ribosylation by PARP10 and PARP14 in genome stability. NAR Cancer. 2023;5:zcad009. https:\/\/doi.org\/10.1093\/narcan\/zcad009.","journal-title":"NAR Cancer"},{"issue":"2","key":"385_CR37","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1101\/gad.291518.116","volume":"31","author":"R Gupte","year":"2017","unstructured":"Gupte R, Liu Z, Kraus WL. PARPs and ADP-ribosylation: recent advances linking molecular functions to biological outcomes. Genes Dev. 2017;31(2):101\u201326. https:\/\/doi.org\/10.1101\/gad.291518.116.","journal-title":"Genes Dev"},{"key":"385_CR38","doi-asserted-by":"publisher","unstructured":"van Beek L, McClay E, Patel S, Schimpl M, Spagnolo L, Maia de Oliveira T. PARP Power: A Structural Perspective on PARP1, PARP2, and PARP3 in DNA Damage Repair and Nucleosome Remodelling. Int J Mol Sci. 2021; 22.https:\/\/doi.org\/10.3390\/ijms22105112.","DOI":"10.3390\/ijms22105112"},{"key":"385_CR39","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1016\/j.tig.2024.08.009","volume":"40","author":"D Huang","year":"2024","unstructured":"Huang D, Su Z, Mei Y, Shao Z. The complex universe of inactive PARP1. Trends Genet. 2024;40:1074\u201385. https:\/\/doi.org\/10.1016\/j.tig.2024.08.009.","journal-title":"Trends Genet"},{"key":"385_CR40","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/s41586-022-05449-8","volume":"612","author":"N Pillay","year":"2022","unstructured":"Pillay N, Mariotti L, Zaleska M, Inian O, Jessop M, Hibbs S, et al. Structural basis of tankyrase activation by polymerization. Nature. 2022;612:162\u20139. https:\/\/doi.org\/10.1038\/s41586-022-05449-8.","journal-title":"Nature"},{"key":"385_CR41","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1038\/nsmb.2523","volume":"20","author":"G Jankevicius","year":"2013","unstructured":"Jankevicius G, Hassler M, Golia B, Rybin V, Zacharias M, Timinszky G, et al. A family of macrodomain proteins reverses cellular mono-ADP-ribosylation. Nat Struct Mol Biol. 2013;20:508\u201314. https:\/\/doi.org\/10.1038\/nsmb.2523.","journal-title":"Nat Struct Mol Biol"},{"key":"385_CR42","doi-asserted-by":"publisher","first-page":"712556","DOI":"10.3389\/fimmu.2021.712556","volume":"12","author":"H Zhu","year":"2021","unstructured":"Zhu H, Tang YD, Zhan G, Su C, Zheng C. The critical role of PARPs in regulating innate immune responses. Front Immunol. 2021;12:712556. https:\/\/doi.org\/10.3389\/fimmu.2021.712556.","journal-title":"Front Immunol"},{"key":"385_CR43","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1038\/nrm3376","volume":"13","author":"BA Gibson","year":"2012","unstructured":"Gibson BA, Kraus WL. New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs. Nat Rev Mol Cell Biol. 2012;13:411\u201324. https:\/\/doi.org\/10.1038\/nrm3376.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"385_CR44","doi-asserted-by":"publisher","unstructured":"Schwarz SD, Xu J, Gunasekera K, Schurmann D, Vagbo CB, Ferrari E, et al. Covalent PARylation of DNA base excision repair proteins regulates DNA demethylation. Nat Commun. 2024; 15:184.https:\/\/doi.org\/10.1038\/s41467-023-44209-8.","DOI":"10.1038\/s41467-023-44209-8"},{"key":"385_CR45","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1038\/sj.emboj.7601015","volume":"25","author":"H Hochegger","year":"2006","unstructured":"Hochegger H, Dejsuphong D, Fukushima T, Morrison C, Sonoda E, Schreiber V, et al. Parp-1 protects homologous recombination from interference by Ku and ligase IV in vertebrate cells. EMBO J. 2006;25:1305\u201314. https:\/\/doi.org\/10.1038\/sj.emboj.7601015.","journal-title":"EMBO J"},{"key":"385_CR46","doi-asserted-by":"publisher","unstructured":"Luijsterburg MS, de Krijger I, Wiegant WW, Shah RG, Smeenk G, de Groot AJL, et al. PARP1 Links CHD2-Mediated Chromatin Expansion and H3.3 Deposition to DNA Repair by Non-homologous End-Joining. Mol Cell. 2016; 61:547\u2013562.https:\/\/doi.org\/10.1016\/j.molcel.2016.01.019.","DOI":"10.1016\/j.molcel.2016.01.019"},{"key":"385_CR47","doi-asserted-by":"publisher","unstructured":"Ray Chaudhuri A, Nussenzweig A. The multifaceted roles of PARP1 in DNA repair and chromatin remodelling. Nat Rev Mol Cell Biol. 2017; 18:610\u2013621.https:\/\/doi.org\/10.1038\/nrm.2017.53.","DOI":"10.1038\/nrm.2017.53"},{"key":"385_CR48","doi-asserted-by":"publisher","first-page":"189282","DOI":"10.1016\/j.bbcan.2025.189282","volume":"1880","author":"CJF Conceicao","year":"2025","unstructured":"Conceicao CJF, Moe E, Ribeiro PA, Raposo M. PARP1: a comprehensive review of its mechanisms, therapeutic implications and emerging cancer treatments. Biochimica et Biophysica Acta (BBA). 2025;1880:189282. https:\/\/doi.org\/10.1016\/j.bbcan.2025.189282.","journal-title":"Biochimica et Biophysica Acta (BBA)"},{"key":"385_CR49","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.semcdb.2016.07.027","volume":"63","author":"T Jubin","year":"2017","unstructured":"Jubin T, Kadam A, Gani AR, Singh M, Dwivedi M, Begum R. Poly ADP-ribose polymerase-1: beyond transcription and towards differentiation. Semin Cell Dev Biol. 2017;63:167\u201379. https:\/\/doi.org\/10.1016\/j.semcdb.2016.07.027.","journal-title":"Semin Cell Dev Biol"},{"key":"385_CR50","doi-asserted-by":"publisher","unstructured":"Zong W, Gong Y, Sun W, Li T, Wang ZQ. PARP1: Liaison of Chromatin Remodeling and Transcription. Cancers (Basel). 2022;14.https:\/\/doi.org\/10.3390\/cancers14174162.","DOI":"10.3390\/cancers14174162"},{"key":"385_CR51","doi-asserted-by":"publisher","unstructured":"Chen H, Gou X, Mao Y, O'Leary PC, Diolaiti ME, Ashworth A. PARP7 Inhibitors and AHR Agonists Act Synergistically across a Wide Range of Cancer Models. Mol Cancer Ther. 2025;24:56\u201368.https:\/\/doi.org\/10.1158\/1535-7163.MCT-24-0211.","DOI":"10.1158\/1535-7163.MCT-24-0211"},{"key":"385_CR52","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1038\/s44321-025-00214-6","volume":"17","author":"K Popova","year":"2025","unstructured":"Popova K, Benedum J, Engl M, Lutgendorf-Caucig C, Fossati P, Widder J, et al. PARP7 as a new target for activating anti-tumor immunity in cancer. EMBO Mol Med. 2025;17:872\u201388. https:\/\/doi.org\/10.1038\/s44321-025-00214-6.","journal-title":"EMBO Mol Med"},{"key":"385_CR53","doi-asserted-by":"publisher","first-page":"941356","DOI":"10.3389\/fcell.2022.941356","volume":"10","author":"P Li","year":"2022","unstructured":"Li P, Lei Y, Qi J, Liu W, Yao K. Functional roles of ADP-ribosylation writers, readers and erasers. Front Cell Dev Biol. 2022;10:941356. https:\/\/doi.org\/10.3389\/fcell.2022.941356.","journal-title":"Front Cell Dev Biol"},{"issue":"14","key":"385_CR54","doi-asserted-by":"publisher","first-page":"2908","DOI":"10.1038\/s44318-024-00125-1","volume":"43","author":"VC Ribeiro","year":"2024","unstructured":"Ribeiro VC, Russo LC, Hoch NC. PARP14 is regulated by the PARP9\/DTX3L complex and promotes interferon \u03b3-induced ADP-ribosylation. EMBO J. 2024;43(14):2908\u201328. https:\/\/doi.org\/10.1038\/s44318-024-00125-1.","journal-title":"EMBO J"},{"key":"385_CR55","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1016\/j.molcel.2022.02.021","volume":"82","author":"D Huang","year":"2022","unstructured":"Huang D, Kraus WL. The expanding universe of PARP1-mediated molecular and therapeutic mechanisms. Mol Cell. 2022;82:2315\u201334. https:\/\/doi.org\/10.1016\/j.molcel.2022.02.021.","journal-title":"Mol Cell"},{"key":"385_CR56","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1093\/nar\/gkad066","volume":"51","author":"N Laspata","year":"2023","unstructured":"Laspata N, Kaur P, Mersaoui SY, Muoio D, Liu ZS, Bannister MH, et al. PARP1 associates with R-loops to promote their resolution and genome stability. Nucleic Acids Res. 2023;51:2215\u201337. https:\/\/doi.org\/10.1093\/nar\/gkad066.","journal-title":"Nucleic Acids Res"},{"key":"385_CR57","doi-asserted-by":"publisher","unstructured":"Li Z, Liu Y, Liu Y, Zhang Y, Huen MSY, Lu H, et al. The PARP1-EXD2 axis orchestrates R-loop resolution to safeguard genome stability. Nat Chem Biol. 2025.https:\/\/doi.org\/10.1038\/s41589-025-01952-x.","DOI":"10.1038\/s41589-025-01952-x"},{"key":"385_CR58","first-page":"3976","volume":"53","author":"SH Kaufmann","year":"1993","unstructured":"Kaufmann SH, Desnoyers S, Ottaviano Y, Davidson NE, Poirier GG. Specific proteolytic cleavage of poly(ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis. Cancer Res. 1993;53:3976\u201385.","journal-title":"Cancer Res"},{"key":"385_CR59","doi-asserted-by":"publisher","first-page":"33533","DOI":"10.1074\/jbc.273.50.33533","volume":"273","author":"FJ Oliver","year":"1998","unstructured":"Oliver FJ, de la Rubia G, Rolli V, Ruiz-Ruiz MC, de Murcia G, Murcia JM. Importance of poly(ADP-ribose) polymerase and its cleavage in apoptosis. Lesson from an uncleavable mutant. J Biol Chem. 1998;273:33533\u20139. https:\/\/doi.org\/10.1074\/jbc.273.50.33533.","journal-title":"J Biol Chem"},{"key":"385_CR60","doi-asserted-by":"publisher","unstructured":"Ryerson MR, Richards MM, Kvansakul M, Hawkins CJ, Shisler JL. Vaccinia Virus Encodes a Novel Inhibitor of Apoptosis That Associates with the Apoptosome. J Virol. 2017; 91:e01385\u201301317.https:\/\/doi.org\/10.1128\/JVI.01385-17.","DOI":"10.1128\/JVI.01385-17"},{"key":"385_CR61","doi-asserted-by":"publisher","unstructured":"Yeganeh B, Ghavami S, Rahim MN, Klonisch T, Halayko AJ, Coombs KM. Autophagy activation is required for influenza A virus-induced apoptosis and replication. Biochim Biophys Acta Mol Cell Res. 2018; 1865:364\u2013378.https:\/\/doi.org\/10.1016\/j.bbamcr.2017.10.014.","DOI":"10.1016\/j.bbamcr.2017.10.014"},{"key":"385_CR62","doi-asserted-by":"publisher","unstructured":"Sun Y, Aliyari SR, Parvatiyar K, Wang L, Zhen A, Sun W, et al. STING directly interacts with PAR to promote apoptosis upon acute ionizing radiation-mediated DNA damage. Cell Death Differ. 2025:1\u201313.https:\/\/doi.org\/10.1038\/s41418-025-01457-z.","DOI":"10.1038\/s41418-025-01457-z"},{"key":"385_CR63","doi-asserted-by":"publisher","first-page":"111935","DOI":"10.1016\/j.yexcr.2020.111935","volume":"390","author":"L Zimmerlin","year":"2020","unstructured":"Zimmerlin L, Zambidis ET. Pleiotropic roles of tankyrase\/PARP proteins in the establishment and maintenance of human naive pluripotency. Exp Cell Res. 2020;390:111935. https:\/\/doi.org\/10.1016\/j.yexcr.2020.111935.","journal-title":"Exp Cell Res"},{"key":"385_CR64","doi-asserted-by":"publisher","unstructured":"Camicia R, Bachmann SB, Winkler HC, Beer M, Tinguely M, Haralambieva E, et al. BAL1\/ARTD9 represses the anti-proliferative and pro-apoptotic IFNgamma-STAT1-IRF1-p53 axis in diffuse large B-cell lymphoma. J Cell Sci. 2013; 126:1969\u20131980.https:\/\/doi.org\/10.1242\/jcs.118174.","DOI":"10.1242\/jcs.118174"},{"key":"385_CR65","doi-asserted-by":"publisher","unstructured":"Iansante V, Choy PM, Fung SW, Liu Y, Chai J-G, Dyson J, et al. PARP14 promotes the Warburg effect in hepatocellular carcinoma by inhibiting JNK1-dependent PKM2 phosphorylation and activation. Nature Communications. 2015;6.https:\/\/doi.org\/10.1038\/ncomms8882","DOI":"10.1038\/ncomms8882"},{"key":"385_CR66","doi-asserted-by":"publisher","unstructured":"David KK, Andrabi SA, Dawson TM, Dawson VL. Parthanatos, a messenger of death. Front Biosci (Landmark Ed). 2009; 14:1116\u20131128.https:\/\/doi.org\/10.2741\/3297.","DOI":"10.2741\/3297"},{"key":"385_CR67","doi-asserted-by":"publisher","unstructured":"Cande C, Cecconi F, Dessen P, Kroemer G. Apoptosis-inducing factor (AIF): key to the conserved caspase-independent pathways of cell death? J Cell Sci. 2002;115:4727\u20134734.https:\/\/doi.org\/10.1242\/jcs.00210.","DOI":"10.1242\/jcs.00210"},{"key":"385_CR68","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1126\/science.1072221","volume":"297","author":"SW Yu","year":"2002","unstructured":"Yu SW, Wang H, Poitras MF, Coombs C, Bowers WJ, Federoff HJ, et al. Mediation of poly(ADP-ribose) polymerase-1-dependent cell death by apoptosis-inducing factor. Science. 2002;297:259\u201363. https:\/\/doi.org\/10.1126\/science.1072221.","journal-title":"Science"},{"key":"385_CR69","doi-asserted-by":"publisher","first-page":"2584","DOI":"10.1091\/mbc.E18-10-0650","volume":"30","author":"MM Murata","year":"2019","unstructured":"Murata MM, Kong X, Moncada E, Chen Y, Imamura H, Wang P, et al. NAD+ consumption by PARP1 in response to DNA damage triggers metabolic shift critical for damaged cell survival. Mol Biol Cell. 2019;30:2584\u201397. https:\/\/doi.org\/10.1091\/mbc.E18-10-0650.","journal-title":"Mol Biol Cell"},{"key":"385_CR70","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1007\/s00018-021-04109-w","volume":"79","author":"L Liu","year":"2022","unstructured":"Liu L, Li J, Ke Y, Zeng X, Gao J, Ba X, et al. The key players of parthanatos: opportunities for targeting multiple levels in the therapy of parthanatos-based pathogenesis. Cell Mol Life Sci. 2022;79:60. https:\/\/doi.org\/10.1007\/s00018-021-04109-w.","journal-title":"Cell Mol Life Sci"},{"key":"385_CR71","doi-asserted-by":"publisher","first-page":"5767","DOI":"10.1007\/s12035-017-0793-y","volume":"55","author":"G Morris","year":"2018","unstructured":"Morris G, Walker AJ, Berk M, Maes M, Puri BK. Cell death pathways: a novel therapeutic approach for neuroscientists. Mol Neurobiol. 2018;55:5767\u201386. https:\/\/doi.org\/10.1007\/s12035-017-0793-y.","journal-title":"Mol Neurobiol"},{"key":"385_CR72","doi-asserted-by":"publisher","first-page":"1943","DOI":"10.1016\/j.cell.2022.04.020","volume":"185","author":"H Park","year":"2022","unstructured":"Park H, Kam TI, Peng H, Chou SC, Mehrabani-Tabari AA, Song JJ, et al. PAAN\/MIF nuclease inhibition prevents neurodegeneration in Parkinson\u2019s disease. Cell. 2022;185:1943\u201359. https:\/\/doi.org\/10.1016\/j.cell.2022.04.020.","journal-title":"Cell"},{"key":"385_CR73","doi-asserted-by":"publisher","first-page":"101928","DOI":"10.1016\/j.redox.2021.101928","volume":"42","author":"T Hong","year":"2021","unstructured":"Hong T, Lei G, Chen X, Li H, Zhang X, Wu N, et al. PARP inhibition promotes ferroptosis via repressing SLC7A11 and synergizes with ferroptosis inducers in BRCA-proficient ovarian cancer. Redox Biol. 2021;42:101928. https:\/\/doi.org\/10.1016\/j.redox.2021.101928.","journal-title":"Redox Biol"},{"key":"385_CR74","doi-asserted-by":"publisher","unstructured":"Huang YL, Huang DY, Klochkov V, Chan CM, Chen YS, Lin WW. NLRX1 Inhibits LPS-Induced Microglial Death via Inducing p62-Dependent HO-1 Expression, Inhibiting MLKL and Activating PARP-1. Antioxidants (Basel). 2024; 13.https:\/\/doi.org\/10.3390\/antiox13040481.","DOI":"10.3390\/antiox13040481"},{"issue":"Suppl 1","key":"385_CR75","doi-asserted-by":"publisher","first-page":"S25","DOI":"10.1002\/epi4.12593","volume":"8","author":"DG Fujikawa","year":"2023","unstructured":"Fujikawa DG. Programmed mechanisms of status epilepticus\u2010induced neuronal necrosis. Epilepsia Open. 2023;8(Suppl 1):S25\u201334. https:\/\/doi.org\/10.1002\/epi4.12593.","journal-title":"Epilepsia Open"},{"key":"385_CR76","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.bbrc.2023.01.055","volume":"646","author":"C Kim","year":"2023","unstructured":"Kim C, Wang XD, Jang S, Yu Y. PARP1 inhibitors induce pyroptosis via caspase 3-mediated gasdermin E cleavage. Biochem Biophys Res Commun. 2023;646:78\u201385. https:\/\/doi.org\/10.1016\/j.bbrc.2023.01.055.","journal-title":"Biochem Biophys Res Commun"},{"key":"385_CR77","doi-asserted-by":"publisher","unstructured":"Richard IA, Burgess JT, O'Byrne KJ, Bolderson E. Beyond PARP1: The Potential of Other 1047 Members of the Poly (ADP-Ribose) Polymerase Family in DNA Repair and Cancer 1048 Therapeutics. Front Cell Dev Biol. 2021;10499:801200. https:\/\/doi.org\/10.3389\/fcell.2021.801200.","DOI":"10.3389\/fcell.2021.801200"},{"key":"385_CR78","doi-asserted-by":"publisher","unstructured":"Zhu H, Zheng C. When PARPs Meet Antiviral Innate Immunity. Trends Microbiol. 2021;29:776\u20138. https:\/\/doi.org\/10.1016\/j.tim.2021.01.002.","DOI":"10.1016\/j.tim.2021.01.002"},{"key":"385_CR79","doi-asserted-by":"publisher","unstructured":"Suskiewicz MJ, Munnur D, Stromland O, Yang JC, Easton LE, Chatrin C, et al. Updated protein 1053 domain annotation of the PARP protein family sheds new light on biological function. 1054 Nucleic Acids Res. 2023;51:8217\u201336. https:\/\/doi.org\/10.1093\/nar\/gkad514.","DOI":"10.1093\/nar\/gkad514"},{"key":"385_CR80","doi-asserted-by":"publisher","unstructured":"Ke Y, Wang C, Zhang J, Zhong X, Wang R, Zeng X, et al. The Role of PARPs in Inflammation-1056 and Metabolic-Related Diseases: Molecular Mechanisms and Beyond. Cells. 2019;8:1057. https:\/\/doi.org\/10.3390\/cells8091047.","DOI":"10.3390\/cells8091047"},{"key":"385_CR81","doi-asserted-by":"publisher","unstructured":"Yang J, Wan SY, Song QY, Xie YH, Wan J, Zhou YH, et al. Angiopoietin-like protein 8 directs 1059 DNA damage responses towards apoptosis by stabilizing PARP1-DNA condensates. Cell 1060 Death Differ. 2025;32:672\u201388. https:\/\/doi.org\/10.1038\/s41418-024-01422-2.","DOI":"10.1038\/s41418-024-01422-2"},{"key":"385_CR82","doi-asserted-by":"publisher","unstructured":"Slade D. Mitotic functions of poly(ADP-ribose) polymerases. Biochem Pharmacol. 2019;167:33\u201343. https:\/\/doi.org\/10.1016\/j.bcp.2019.03.028.","DOI":"10.1016\/j.bcp.2019.03.028"},{"key":"385_CR83","doi-asserted-by":"publisher","unstructured":"Mashimo M, Kita M, Nobeyama A, Nomura A, Fujii T. PARP1 is activated by membrane 1064 damage and is involved in membrane repair through poly(ADP-ribosyl)ation. Genes Cells. 2022;27:305\u201312. https:\/\/doi.org\/10.1111\/gtc.12926.","DOI":"10.1111\/gtc.12926"},{"key":"385_CR84","doi-asserted-by":"publisher","unstructured":"Beck C, Robert I, Reina-San-Martin B, Schreiber V, Dantzer F. Poly(ADP-ribose) polymerases 1067 in double-strand break repair: focus on PARP1, PARP2 and PARP3. Exp Cell Res. 2014;329:18\u201325. https:\/\/doi.org\/10.1016\/j.yexcr.2014.07.003.","DOI":"10.1016\/j.yexcr.2014.07.003"},{"key":"385_CR85","doi-asserted-by":"publisher","unstructured":"Bilkis R, Lake RJ, Cooper KL, Tomkinson A, Fan HY. The CSB chromatin remodeler regulates 1070 PARP1- and PARP2-mediated single-strand break repair at actively transcribed DNA 1071 regions. Nucleic Acids Res. 2023;51:7342\u201356. https:\/\/doi.org\/10.1093\/nar\/gkad515.","DOI":"10.1093\/nar\/gkad515"},{"key":"385_CR86","doi-asserted-by":"publisher","unstructured":"Kutuzov MM, Belousova EA, Ilina ES, Lavrik OI. Impact of PARP1, PARP2 & PARP3 on the 1073 Base Excision Repair of Nucleosomal DNA. Adv Exp Med Biol. 2020;1241:47\u201357. https:\/\/doi.org\/10.1007\/978-3-030-41283-8_4.","DOI":"10.1007\/978-3-030-41283-8_4"},{"key":"385_CR87","doi-asserted-by":"publisher","unstructured":"Muoio D, Laspata N, Dannenberg RL, Curry C, Darkoa-Larbi S, Hedglin M, et al. PARP2 1076 promotes Break Induced Replication-mediated telomere fragility in response to replication 1077 stress. Nat Commun. 2024;15:2857. https:\/\/doi.org\/10.1038\/s41467-024-47222-7.","DOI":"10.1038\/s41467-024-47222-7"},{"key":"385_CR88","doi-asserted-by":"publisher","unstructured":"Zheng GD, Hu PJ, Chao YX, Zhou Y, Yang XJ, Chen BZ, et al. Nobiletin induces growth 1079 inhibition and apoptosis in human nasopharyngeal carcinoma C666-1 cells through regulating PARP-2\/SIRT1\/AMPK signaling pathway. Food Sci Nutr. 2019;7:1104\u201312. https:\/\/doi.org\/10.1002\/fsn3.953.","DOI":"10.1002\/fsn3.953"},{"key":"385_CR89","doi-asserted-by":"publisher","unstructured":"Meng XW, Koh BD, Zhang JS, Flatten KS, Schneider PA, Billadeau DD, et al. Poly(ADP-1083 ribose) polymerase inhibitors sensitize cancer cells to death receptor-mediated apoptosis 1084 by enhancing death receptor expression. J Biol Chem. 2014;289:20543\u201358. https:\/\/doi.org\/10.1074\/jbc.M114.549220.","DOI":"10.1074\/jbc.M114.549220"},{"key":"385_CR90","doi-asserted-by":"publisher","unstructured":"Beck C, Rodriguez-Vargas JM, Boehler C, Robert I, Heyer V, Hanini N, et al. PARP3, a new 1087 therapeutic target to alter Rictor\/mTORC2 signaling and tumor progression in BRCA1-1088 associated cancers. Cell Death Differ. 2019;26:1615\u201330. https:\/\/doi.org\/10.1038\/s41418-1089018-0233-1.","DOI":"10.1038\/s41418-1089018-0233-1"},{"key":"385_CR91","doi-asserted-by":"publisher","unstructured":"Padella A, Ghelli Luserna Di Rora A, Marconi G, Ghetti M, Martinelli G, Simonetti G. 1091 Targeting PARP proteins in acute leukemia: DNA damage response inhibition and 1092 therapeutic strategies. J Hematol Oncol. 2022;15:10. https:\/\/doi.org\/10.1186\/s13045-022-109301228-0.","DOI":"10.1186\/s13045-022-109301228-0"},{"key":"385_CR92","doi-asserted-by":"publisher","unstructured":"Shelke GV, Jagtap JC, Kim DK, Shah RD, Das G, Shivayogi M, et al. TNF-alpha and IFN-1095 gamma Together Up-Regulates Par-4 Expression and Induce Apoptosis in Human 1096 Neuroblastomas. Biomedicines. 2017;6. https:\/\/doi.org\/10.3390\/biomedicines6010004.","DOI":"10.3390\/biomedicines6010004"},{"key":"385_CR93","doi-asserted-by":"publisher","unstructured":"Li Y, Liu Y, Ma J, Yang Y, Yue Q, Zhu G, et al. PARP4 deficiency enhances sensitivity to ATM 1098 inhibitor by impairing DNA damage repair in melanoma. Cell Death Discov. 2025;11:35. https:\/\/doi.org\/10.1038\/s41420-025-02296-0.","DOI":"10.1038\/s41420-025-02296-0"},{"key":"385_CR94","doi-asserted-by":"publisher","unstructured":"Frigon L, Pascal JM. Crystal structure and mutagenesis of a nucleic acid-binding BRCT domain 1101 in human PARP4. J Biol Chem. 2025;301:110277. https:\/\/doi.org\/10.1016\/j.jbc.2025.110277.","DOI":"10.1016\/j.jbc.2025.110277"},{"key":"385_CR95","doi-asserted-by":"publisher","unstructured":"DaRosa PA, Klevit RE, Xu W. Structural basis for tankyrase-RNF146 interaction reveals 1104 noncanonical tankyrase-binding motifs. Protein Sci. 2018;27:1057\u2013105. https:\/\/doi.org\/10.1002\/pro.3413.","DOI":"10.1002\/pro.3413"},{"key":"385_CR96","doi-asserted-by":"publisher","unstructured":"Hou S, Zhang J, Jiang X, Yang Y, Shan B, Zhang M, et al. PARP5A and RNF146 phase 1107 separation restrains RIPK1-dependent necroptosis. Mol Cell. 2024;84:938\u201354.e938. https:\/\/doi.org\/10.1016\/j.molcel.2023.12.041.","DOI":"10.1016\/j.molcel.2023.12.041"},{"key":"385_CR97","doi-asserted-by":"publisher","unstructured":"Zhou B, Jiang ZH, Dai MR, Ai YL, Xiao L, Zhong CQ, et al. Full-length GSDME mediates 1110 pyroptosis independent from cleavage. Nat Cell Biol. 2024;26:1545\u201357. https:\/\/doi.org\/10.1038\/s41556-024-01463-2.","DOI":"10.1038\/s41556-024-01463-2"},{"key":"385_CR98","doi-asserted-by":"publisher","unstructured":"Huang JY, Wang K, Vermehren-Schmaedick A, Adelman JP, Cohen MS. PARP6 is a Regulator 1113 of Hippocampal Dendritic Morphogenesis. Sci Rep. 2016;6:18512. https:\/\/doi.org\/10.1038\/srep18512.","DOI":"10.1038\/srep18512"},{"key":"385_CR99","doi-asserted-by":"publisher","unstructured":"Manetsch P, Bohi F, Nowak K, Leslie Pedrioli DM, Hottiger MO. PARP7-mediated ADP-1116 ribosylation of FRA1 promotes cancer cell growth by repressing IRF1- and IRF3-1117 dependent apoptosis. Proc Natl Acad Sci U S A. 2023;120:e2309047120. https:\/\/doi.org\/10.1073\/pnas.2309047120.","DOI":"10.1073\/pnas.2309047120"},{"key":"385_CR100","doi-asserted-by":"publisher","unstructured":"Gu H, Yan W, Yang J, Liu B, Zhao X, Wang H, et al. Discovery of Highly Selective PARP7 1120 Inhibitors with a Novel Scaffold for Cancer Immunotherapy. J Med Chem. 2024;67:1932\u201348. https:\/\/doi.org\/10.1021\/acs.jmedchem.3c01764.","DOI":"10.1021\/acs.jmedchem.3c01764"},{"key":"385_CR101","doi-asserted-by":"publisher","unstructured":"Gozgit JM, Vasbinder MM, Abo RP, Kunii K, Kuplast-Barr KG, Gui B, et al. PARP7 1123 negatively regulates the type I interferon response in cancer cells and its inhibition triggers 1124 antitumor immunity. Cancer Cell. 2021;39:1214\u201326.e1210. https:\/\/doi.org\/10.1016\/j.ccell.2021.06.018.","DOI":"10.1016\/j.ccell.2021.06.018"},{"key":"385_CR102","doi-asserted-by":"publisher","unstructured":"Szanto M, Gupte R, Kraus WL, Pacher P, Bai P. PARPs in lipid metabolism and related 1127 diseases. Prog Lipid Res. 2021;84:101117. https:\/\/doi.org\/10.1016\/j.plipres.2021.101117.","DOI":"10.1016\/j.plipres.2021.101117"},{"key":"385_CR103","doi-asserted-by":"publisher","unstructured":"Bora NR, Kumar R, Kumar S. Development of an apoptotic lentogenic Newcastle disease 1129 virus strain by incorporating the p30 protein of African swine fever virus. Virology. 2025;1130 606. https:\/\/doi.org\/10.1016\/j.virol.2025.110477.","DOI":"10.1016\/j.virol.2025.110477"},{"key":"385_CR104","doi-asserted-by":"publisher","unstructured":"Robert I, Gaudot L, Yelamos J, Noll A, Wong HK, Dantzer F, et al. Robust immunoglobulin 1132 class switch recombination and end joining in Parp9-deficient mice. Eur J Immunol. 2017;47:665\u201376. https:\/\/doi.org\/10.1002\/eji.201646757.","DOI":"10.1002\/eji.201646757"},{"key":"385_CR105","doi-asserted-by":"publisher","unstructured":"Herzog N, Hartkamp JD, Verheugd P, Treude F, Forst AH, Feijs KL, et al. Caspase-dependent 1135 cleavage of the mono-ADP-ribosyltransferase ARTD10 interferes with its pro-apoptotic 1136 function. FEBS J. 2013;280:1330\u201343. https:\/\/doi.org\/10.1111\/febs.12124.","DOI":"10.1111\/febs.12124"},{"key":"385_CR106","doi-asserted-by":"publisher","unstructured":"Khatib JB, Dhoonmoon A, Moldovan GL, Nicolae CM. PARP10 promotes the repair of 1138 nascent strand DNA gaps through RAD18 mediated translesion synthesis. Nat Commun. 2024;15:6197. https:\/\/doi.org\/10.1038\/s41467-024-50429-3.","DOI":"10.1038\/s41467-024-50429-3"},{"key":"385_CR107","doi-asserted-by":"publisher","unstructured":"Cao G, Guo R, Chen M, Sun C, Wang J. PARP12 regulates mouse oocyte meiotic maturation. 1141 J Cell Physiol. 2023;238:1580\u201391. https:\/\/doi.org\/10.1002\/jcp.31037.","DOI":"10.1002\/jcp.31037"},{"key":"385_CR108","doi-asserted-by":"publisher","unstructured":"Todorova T, Bock FJ, Chang P. Poly(ADP-ribose) polymerase-13 and RNA regulation in 1036 immunity and cancer. Trends Mol Med. 2015;21:373\u201384. https:\/\/doi.org\/10.1016\/j.molmed.2015.03.002.","DOI":"10.1016\/j.molmed.2015.03.002"},{"key":"385_CR109","doi-asserted-by":"publisher","unstructured":"Todorova T, Bock FJ, Chang P. PARP13 regulates cellular mRNA post-transcriptionally and 1143 functions as a pro-apoptotic factor by destabilizing TRAILR4 transcript. Nat Commun. 2014;5:5362. https:\/\/doi.org\/10.1038\/ncomms6362.","DOI":"10.1038\/ncomms6362"},{"key":"385_CR110","doi-asserted-by":"publisher","unstructured":"Im JY, Kim SJ, Park JL, Han TH, Kim WI, Kim I, et al. CYB5R3 functions as a tumor 1146 suppressor by inducing ER stress-mediated apoptosis in lung cancer cells via the PERK-1147 ATF4 and IRE1alpha-JNK pathways. Exp Mol Med. 2024;56:235\u201349. https:\/\/doi.org\/10.1038\/s12276-024-01155-9.","DOI":"10.1038\/s12276-024-01155-9"},{"key":"385_CR111","doi-asserted-by":"publisher","unstructured":"Jwa M, Chang P. PARP16 is a tail-anchored endoplasmic reticulum protein required for the 1150 PERK- and IRE1\u03b1-mediated unfolded protein response. Nature Cell Biology. 2012;14:1223\u201330. https:\/\/doi.org\/10.1038\/ncb2593.","DOI":"10.1038\/ncb2593"},{"key":"385_CR112","doi-asserted-by":"publisher","unstructured":"Wang J, Cheng Q, Zhang Y, Hong C, Liu J, Liu X, et al. PARP16-Mediated Stabilization of 1153 Amyloid Precursor Protein mRNA Exacerbates Alzheimer's Disease Pathogenesis. Aging 1154 Dis. 2023;14:1458\u201371. https:\/\/doi.org\/10.14336\/AD.2023.0119.","DOI":"10.14336\/AD.2023.0119"},{"key":"385_CR113","doi-asserted-by":"publisher","unstructured":"Alemasova EE, Lavrik OI. Poly(ADP-ribosyl)ation by PARP1: reaction mechanism and 1030 regulatory proteins. Nucleic Acids Res. 2019;47:3811\u201327. https:\/\/doi.org\/10.1093\/nar\/gkz120.","DOI":"10.1093\/nar\/gkz120"},{"key":"385_CR114","doi-asserted-by":"publisher","unstructured":"Genois MM, Gagne JP, Yasuhara T, Jackson J, Saxena S, Langelier MF, et al. CARM1 regulates 1033 replication fork speed and stress response by stimulating PARP1. Mol Cell. 2021;81:784\u2013800.e788. https:\/\/doi.org\/10.1016\/j.molcel.2020.12.010.","DOI":"10.1016\/j.molcel.2020.12.010"},{"key":"385_CR115","doi-asserted-by":"publisher","unstructured":"Liao M, Long X, Chen Y, An J, Huang W, Xu X, et al. PARP9 exacerbates apoptosis and 1039 neuroinflammation via the PI3K pathway in the thalamus and hippocampus and cognitive 1040 decline after cortical infarction. J Neuroinflammation. 2025;22:43. https:\/\/doi.org\/10.1186\/s12974-025-03374-x.","DOI":"10.1186\/s12974-025-03374-x"},{"key":"385_CR116","doi-asserted-by":"publisher","unstructured":"Sukhanova MV, Hamon L, Kutuzov MM, Joshi V, Abrakhi S, Dobra I, et al. A Single-Molecule 1043 Atomic Force Microscopy Study of PARP1 and PARP2 Recognition of Base Excision 1044 Repair DNA Intermediates. J Mol Biol. 2019;431:2655\u201373. https:\/\/doi.org\/10.1016\/j.jmb.2019.05.028.","DOI":"10.1016\/j.jmb.2019.05.028"},{"key":"385_CR117","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1093\/nar\/gkab020","volume":"49","author":"TEH Ogden","year":"2021","unstructured":"Ogden TEH, Yang JC, Schimpl M, Easton LE, Underwood E, Rawlins PB, et al. Dynamics of the HD regulatory subdomain of PARP-1; substrate access and allostery in PARP activation and inhibition. Nucleic Acids Res. 2021;49:2266\u201388. https:\/\/doi.org\/10.1093\/nar\/gkab020.","journal-title":"Nucleic Acids Res"},{"key":"385_CR118","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1097\/GCO.0b013e328334ff57","volume":"22","author":"Y Drew","year":"2010","unstructured":"Drew Y, Plummer R. The emerging potential of poly(ADP-ribose) polymerase inhibitors in the treatment of breast cancer. Curr Opin Obstet Gynecol. 2010;22:67\u201371. https:\/\/doi.org\/10.1097\/GCO.0b013e328334ff57.","journal-title":"Curr Opin Obstet Gynecol"},{"key":"385_CR119","doi-asserted-by":"publisher","first-page":"5588","DOI":"10.1158\/0008-5472.CAN-12-2753","volume":"72","author":"J Murai","year":"2012","unstructured":"Murai J, Huang SY, Das BB, Renaud A, Zhang Y, Doroshow JH, et al. Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res. 2012;72:5588\u201399. https:\/\/doi.org\/10.1158\/0008-5472.CAN-12-2753.","journal-title":"Cancer Res"},{"key":"385_CR120","doi-asserted-by":"publisher","first-page":"5616","DOI":"10.1093\/nar\/gku174","volume":"42","author":"C Beck","year":"2014","unstructured":"Beck C, Boehler C, Guirouilh Barbat J, Bonnet ME, Illuzzi G, Ronde P, et al. PARP3 affects the relative contribution of homologous recombination and nonhomologous end-joining pathways. Nucleic Acids Res. 2014;42:5616\u201332. https:\/\/doi.org\/10.1093\/nar\/gku174.","journal-title":"Nucleic Acids Res"},{"key":"385_CR121","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1101\/gad.251785.114","volume":"29","author":"N Li","year":"2015","unstructured":"Li N, Zhang Y, Han X, Liang K, Wang J, Feng L, et al. Poly-ADP ribosylation of PTEN by tankyrases promotes PTEN degradation and tumor growth. Genes Dev. 2015;29:157\u201370. https:\/\/doi.org\/10.1101\/gad.251785.114.","journal-title":"Genes Dev"},{"key":"385_CR122","doi-asserted-by":"publisher","first-page":"105299","DOI":"10.1016\/j.phrs.2020.105299","volume":"163","author":"Y Zhou","year":"2021","unstructured":"Zhou Y, Liu L, Tao S, Yao Y, Wang Y, Wei Q, et al. Parthanatos and its associated components: promising therapeutic targets for cancer. Pharmacol Res. 2021;163:105299. https:\/\/doi.org\/10.1016\/j.phrs.2020.105299.","journal-title":"Pharmacol Res"},{"key":"385_CR123","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1038\/s41418-025-01457-z","volume":"32","author":"Y Sun","year":"2025","unstructured":"Sun Y, Aliyari SR, Parvatiyar K, Wang L, Zhen A, Sun W, et al. STING directly interacts with PAR to promote apoptosis upon acute ionizing radiation-mediated DNA damage. Cell Death Differ. 2025;32:1167\u201379. https:\/\/doi.org\/10.1038\/s41418-025-01457-z.","journal-title":"Cell Death Differ"},{"key":"385_CR124","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1186\/s13046-025-03482-9","volume":"44","author":"R Guan","year":"2025","unstructured":"Guan R, Li C, Jiao R, Li J, Wei R, Feng C, et al. MRPL21-PARP1 axis promotes cisplatin resistance in head and neck squamous cell carcinoma by inhibiting autophagy through the PI3K\/AKT\/mTOR signaling pathway. J Exp Clin Cancer Res. 2025;44:221. https:\/\/doi.org\/10.1186\/s13046-025-03482-9.","journal-title":"J Exp Clin Cancer Res"},{"key":"385_CR125","doi-asserted-by":"publisher","first-page":"110782","DOI":"10.1016\/j.cellsig.2023.110782","volume":"109","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Wu K, Liu Y, Sun S, Shao Y, Li Q, et al. UHRF2 promotes the malignancy of hepatocellular carcinoma by PARP1 mediated autophagy. Cell Signal. 2023;109:110782. https:\/\/doi.org\/10.1016\/j.cellsig.2023.110782.","journal-title":"Cell Signal"},{"issue":"2","key":"385_CR126","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/s0304-3835(03)00148-4","volume":"195","author":"M Zhang","year":"2003","unstructured":"Zhang M, Guo R, Zhai Y, Yang D. LIGHT sensitizes IFN\u03b3-mediated apoptosis of MDA-MB-231 breast cancer cells leading to down-regulation of anti-apoptosis Bcl-2 family members. Cancer Lett. 2003;195(2):201\u201310. https:\/\/doi.org\/10.1016\/s0304-3835(03)00148-4.","journal-title":"Cancer Lett"},{"key":"385_CR127","doi-asserted-by":"publisher","unstructured":"Li Q, Kawamura K, Ma G, Iwata F, Numasaki M, Suzuki N, et al. Interferon-lambda induces G1 phase arrest or apoptosis in oesophageal carcinoma cells and produces anti-tumour effects in combination with anti-cancer agents. Eur J Cancer. 2010; 46:180\u2013190.https:\/\/doi.org\/10.1016\/j.ejca.2009.10.002.","DOI":"10.1016\/j.ejca.2009.10.002"},{"key":"385_CR128","doi-asserted-by":"publisher","first-page":"102402","DOI":"10.1016\/j.cbpa.2023.102402","volume":"77","author":"DM Brooks","year":"2023","unstructured":"Brooks DM, Anand S, Cohen MS. Immunomodulatory roles of PARPs: shaping the tumor microenvironment, one ADP-ribose at a time. Curr Opin Chem Biol. 2023;77:102402. https:\/\/doi.org\/10.1016\/j.cbpa.2023.102402.","journal-title":"Curr Opin Chem Biol"},{"key":"385_CR129","doi-asserted-by":"publisher","unstructured":"Chan N, Pires IM, Bencokova Z, Coackley C, Luoto KR, Bhogal N, et al. Contextual synthetic lethality of cancer cell kill based on the tumor microenvironment. Cancer Res. 2010; 70:8045\u20138054.https:\/\/doi.org\/10.1158\/0008-5472.CAN-10-2352.","DOI":"10.1158\/0008-5472.CAN-10-2352"},{"key":"385_CR130","doi-asserted-by":"publisher","first-page":"114770","DOI":"10.1016\/j.biopha.2023.114770","volume":"163","author":"XF Yi","year":"2023","unstructured":"Yi XF, Gao RL, Sun L, Wu ZX, Zhang SL, Huang LT, et al. Dual antitumor immunomodulatory effects of PARP inhibitor on the tumor microenvironment: a counterbalance between anti-tumor and pro-tumor. Biomed Pharmacother. 2023;163:114770. https:\/\/doi.org\/10.1016\/j.biopha.2023.114770.","journal-title":"Biomed Pharmacother"},{"key":"385_CR131","doi-asserted-by":"publisher","first-page":"E4061","DOI":"10.1073\/pnas.1712345115","volume":"115","author":"B Dorsam","year":"2018","unstructured":"Dorsam B, Seiwert N, Foersch S, Stroh S, Nagel G, Begaliew D, et al. PARP-1 protects against colorectal tumor induction, but promotes inflammation-driven colorectal tumor progression. Proc Natl Acad Sci U S A. 2018;115:E4061\u201370. https:\/\/doi.org\/10.1073\/pnas.1712345115.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"385_CR132","doi-asserted-by":"publisher","unstructured":"Sturniolo I, Varoczy C, Regdon Z, Mazlo A, Muzsai S, Bacsi A, et al. PARP14 Contributes to the Development of the Tumor-Associated Macrophage Phenotype. Int J Mol Sci. 2024; 25.https:\/\/doi.org\/10.3390\/ijms25073601.","DOI":"10.3390\/ijms25073601"},{"key":"385_CR133","doi-asserted-by":"publisher","first-page":"2281","DOI":"10.1038\/s41375-022-01641-x","volume":"36","author":"M Mentz","year":"2022","unstructured":"Mentz M, Keay W, Strobl CD, Antoniolli M, Adolph L, Heide M, et al. PARP14 is a novel target in STAT6 mutant follicular lymphoma. Leukemia. 2022;36:2281\u201392. https:\/\/doi.org\/10.1038\/s41375-022-01641-x.","journal-title":"Leukemia"},{"key":"385_CR134","doi-asserted-by":"publisher","unstructured":"Palavalli Parsons LH, Challa S, Gibson BA, Nandu T, Stokes MS, Huang D, et al. Identification of PARP-7 substrates reveals a role for MARylation in microtubule control in ovarian cancer cells. Elife. 2021; 10.https:\/\/doi.org\/10.7554\/eLife.60481.","DOI":"10.7554\/eLife.60481"},{"key":"385_CR135","doi-asserted-by":"publisher","unstructured":"Humer D, Klepsch V, Baier G. Potentiation of cancer immunogenicity by targeting PARP. J Immunother Cancer. 2025; 13.https:\/\/doi.org\/10.1136\/jitc-2024-011056.","DOI":"10.1136\/jitc-2024-011056"},{"key":"385_CR136","doi-asserted-by":"publisher","first-page":"4905","DOI":"10.1016\/j.cell.2024.06.013","volume":"187","author":"Y Luo","year":"2024","unstructured":"Luo Y, Xia Y, Liu D, Li X, Li H, Liu J, et al. Neoadjuvant PARpi or chemotherapy in ovarian cancer informs targeting effector Treg cells for homologous-recombination-deficient tumors. Cell. 2024;187:4905. https:\/\/doi.org\/10.1016\/j.cell.2024.06.013.","journal-title":"Cell"},{"key":"385_CR137","doi-asserted-by":"publisher","first-page":"106425","DOI":"10.1016\/j.phrs.2022.106425","volume":"184","author":"S Paul","year":"2022","unstructured":"Paul S, Sinha S, Kundu CN. Targeting cancer stem cells in the tumor microenvironment: an emerging role of PARP inhibitors. Pharmacol Res. 2022;184:106425. https:\/\/doi.org\/10.1016\/j.phrs.2022.106425.","journal-title":"Pharmacol Res"},{"key":"385_CR138","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1038\/s41419-025-07939-9","volume":"16","author":"J Shen","year":"2025","unstructured":"Shen J, Xu F, Liu T, Ye Y, Xu S. NAD(+) metabolism-mediated SURF4-STING axis enhances T-cell anti-tumor effects in the ovarian cancer microenvironment. Cell Death Dis. 2025;16:640. https:\/\/doi.org\/10.1038\/s41419-025-07939-9.","journal-title":"Cell Death Dis"},{"key":"385_CR139","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1038\/s41467-025-57257-z","volume":"16","author":"X Ran","year":"2025","unstructured":"Ran X, Wu BX, Vidhyasagar V, Song L, Zhang X, Ladak RJ, et al. PARP inhibitor radiosensitization enhances anti-PD-L1 immunotherapy through stabilizing chemokine mRNA in small cell lung cancer. Nat Commun. 2025;16:2166. https:\/\/doi.org\/10.1038\/s41467-025-57257-z.","journal-title":"Nat Commun"},{"key":"385_CR140","doi-asserted-by":"publisher","first-page":"2814","DOI":"10.1158\/0008-5472.CAN-11-3417","volume":"72","author":"S Ying","year":"2012","unstructured":"Ying S, Hamdy FC, Helleday T. Mre11-dependent degradation of stalled DNA replication forks is prevented by BRCA2 and PARP1. Cancer Res. 2012;72:2814\u201321. https:\/\/doi.org\/10.1158\/0008-5472.CAN-11-3417.","journal-title":"Cancer Res"},{"key":"385_CR141","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1038\/s41467-018-03159-2","volume":"9","author":"GE Ronson","year":"2018","unstructured":"Ronson GE, Piberger AL, Higgs MR, Olsen AL, Stewart GS, McHugh PJ, et al. PARP1 and PARP2 stabilise replication forks at base excision repair intermediates through Fbh1-dependent Rad51 regulation. Nat Commun. 2018;9:746. https:\/\/doi.org\/10.1038\/s41467-018-03159-2.","journal-title":"Nat Commun"},{"key":"385_CR142","doi-asserted-by":"publisher","first-page":"5676","DOI":"10.1093\/nar\/gkae211","volume":"52","author":"CK Wu","year":"2024","unstructured":"Wu CK, Shiu JL, Wu CL, Hung CF, Ho YC, Chen YT, et al. APLF facilitates interstrand DNA crosslink repair and replication fork protection to confer cisplatin resistance. Nucleic Acids Res. 2024;52:5676\u201397. https:\/\/doi.org\/10.1093\/nar\/gkae211.","journal-title":"Nucleic Acids Res"},{"key":"385_CR143","doi-asserted-by":"publisher","unstructured":"Nicolae CM, Aho ER, Vlahos AH, Choe KN, De S, Karras GI, et al. The ADP-ribosyltransferase PARP10\/ARTD10 interacts with proliferating cell nuclear antigen (PCNA) and is required for DNA damage tolerance. J Biol Chem. 2014; 289:13627\u201313637.https:\/\/doi.org\/10.1074\/jbc.M114.556340.","DOI":"10.1074\/jbc.M114.556340"},{"key":"385_CR144","doi-asserted-by":"publisher","unstructured":"Demeny MA, Virag L. The PARP Enzyme Family and the Hallmarks of Cancer Part 1. Cell Intrinsic Hallmarks. Cancers (Basel). 2021; 13.https:\/\/doi.org\/10.3390\/cancers13092042.","DOI":"10.3390\/cancers13092042"},{"issue":"7","key":"385_CR145","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1158\/1535-7163.MCT-21-0841","volume":"21","author":"H Chen","year":"2022","unstructured":"Chen H, Diolaiti ME, O\u2019Leary PC, Rojc A, Krogan NJ, Kim M, et al. A whole-genome CRISPR screen identifies AHR loss as a mechanism of resistance to a PARP7 inhibitor. Mol Cancer Ther. 2022;21(7):1076\u201389. https:\/\/doi.org\/10.1158\/1535-7163.MCT-21-0841.","journal-title":"Mol Cancer Ther"},{"key":"385_CR146","doi-asserted-by":"publisher","first-page":"109094","DOI":"10.1016\/j.clim.2022.109094","volume":"242","author":"Y Zhu","year":"2022","unstructured":"Zhu Y, Liu Z, Wan Y, Zou L, Liu L, Ding S, et al. PARP14 promotes the growth and glycolysis of acute myeloid leukemia cells by regulating HIF-1\u03b1 expression. Clin Immunol. 2022;242:109094. https:\/\/doi.org\/10.1016\/j.clim.2022.109094.","journal-title":"Clin Immunol"},{"key":"385_CR147","doi-asserted-by":"publisher","unstructured":"Li Z, Luo A, Xie B. The Complex Network of ADP-Ribosylation and DNA Repair: Emerging Insights and Implications for Cancer Therapy. Int J Mol Sci. 2023; 24.https:\/\/doi.org\/10.3390\/ijms241915028.","DOI":"10.3390\/ijms241915028"},{"key":"385_CR148","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1016\/j.jmb.2019.12.019","volume":"432","author":"HH Sutcu","year":"2020","unstructured":"Sutcu HH, Matta E, Ishchenko AA. Role of PARP-catalyzed ADP-ribosylation in the crosstalk between DNA strand breaks and epigenetic regulation. J Mol Biol. 2020;432:1769\u201391. https:\/\/doi.org\/10.1016\/j.jmb.2019.12.019.","journal-title":"J Mol Biol"},{"issue":"11","key":"385_CR149","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1038\/s41564-019-0428-3","volume":"4","author":"T Guo","year":"2019","unstructured":"Guo T, Zuo Y, Qian L, Liu J, Yuan Y, Xu K, et al. ADP-ribosyltransferase PARP11 modulates the interferon antiviral response by mono-ADP-ribosylating the ubiquitin E3 ligase \u03b2-TrCP. Nat Microbiol. 2019;4(11):1872\u201384. https:\/\/doi.org\/10.1038\/s41564-019-0428-3.","journal-title":"Nat Microbiol"},{"issue":"7","key":"385_CR150","doi-asserted-by":"publisher","first-page":"e70013","DOI":"10.1002\/ddr.70013","volume":"85","author":"X Du","year":"2024","unstructured":"Du X, Zhou J, Zhou Y, Chen Y, Kang Y, Zhao D, et al. PARP7i Clinical Candidate RBN\u20102397 Exerts Antiviral Activity by Modulating Interferon\u2010\u03b2 Associated Innate Immune Response in Macrophages. Drug Dev Res. 2024;85(7):e70013. https:\/\/doi.org\/10.1002\/ddr.70013.","journal-title":"Drug Dev Res"},{"issue":"1","key":"385_CR151","doi-asserted-by":"publisher","first-page":"2681","DOI":"10.1038\/s41467-021-23003-4","volume":"12","author":"J Xing","year":"2021","unstructured":"Xing J, Zhang A, Du Y, Fang M, Minze LJ, Liu YJ, et al. Identification of poly(ADP-ribose) polymerase 9 (PARP9) as a noncanonical sensor for RNA virus in dendritic cells. Nat Commun. 2021;12(1):2681. https:\/\/doi.org\/10.1038\/s41467-021-23003-4.","journal-title":"Nat Commun"},{"key":"385_CR152","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1038\/ni.3279","volume":"16","author":"Y Zhang","year":"2015","unstructured":"Zhang Y, Mao D, Roswit WT, Jin X, Patel AC, Patel DA, et al. PARP9-DTX3L ubiquitin ligase targets host histone H2BJ and viral 3C protease to enhance interferon signaling and control viral infection. Nat Immunol. 2015;16:1215\u201327. https:\/\/doi.org\/10.1038\/ni.3279.","journal-title":"Nat Immunol"},{"key":"385_CR153","doi-asserted-by":"publisher","unstructured":"Kar P, Chatrin C, Dukic N, Suyari O, Schuller M, Zhu K, et al. PARP14 and PARP9\/DTX3L regulate interferon-induced ADP-ribosylation. EMBO J. 2024; 43:2929\u20132953.https:\/\/doi.org\/10.1038\/s44318-024-00126-0.","DOI":"10.1038\/s44318-024-00126-0"},{"key":"385_CR154","doi-asserted-by":"publisher","unstructured":"Lin Z, Li Y, Gong G, Xia Y, Wang C, Chen Y, et al. Restriction of H1N1 influenza virus infection by selenium nanoparticles loaded with ribavirin via resisting caspase-3 apoptotic pathway. Int J Nanomedicine. 2018; 13:5787\u20135797.https:\/\/doi.org\/10.2147\/IJN.S177658.","DOI":"10.2147\/IJN.S177658"},{"key":"385_CR155","doi-asserted-by":"publisher","first-page":"e2426660122","DOI":"10.1073\/pnas.2426660122","volume":"122","author":"X Huang","year":"2025","unstructured":"Huang X, Li F, Liu L, Li Y, Zhang M, Ma G, et al. PARP12-mediated mono-ADP-ribosylation as a checkpoint for necroptosis and apoptosis. Proc Natl Acad Sci U S A. 2025;122:e2426660122. https:\/\/doi.org\/10.1073\/pnas.2426660122.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"385_CR156","doi-asserted-by":"publisher","unstructured":"Westera L, Jennings AM, Maamary J, Schwemmle M, Garcia-Sastre A, Bortz E. Poly-ADP Ribosyl Polymerase 1 (PARP1) Regulates Influenza A Virus Polymerase. Adv Virol. 2019; 2019:8512363.https:\/\/doi.org\/10.1155\/2019\/8512363.","DOI":"10.1155\/2019\/8512363"},{"key":"385_CR157","doi-asserted-by":"publisher","first-page":"754190","DOI":"10.1155\/2008\/754190","volume":"2008","author":"TS Piskunova","year":"2008","unstructured":"Piskunova TS, Yurova MN, Ovsyannikov AI, Semenchenko AV, Zabezhinski MA, Popovich IG, et al. Deficiency in poly(ADP-ribose) polymerase-1 (PARP-1) accelerates aging and spontaneous carcinogenesis in mice. Curr Gerontol Geriatr Res. 2008;2008:754190. https:\/\/doi.org\/10.1155\/2008\/754190.","journal-title":"Curr Gerontol Geriatr Res"},{"key":"385_CR158","doi-asserted-by":"publisher","unstructured":"Yuan J, Li R, Song H, Liu X. Sirtuin3 Alleviated Influenza A Virus-Induced Mitochondrial Oxidative Stress and Inflammation in Lung Epithelial Cells via Regulating Poly (ADP-Ribose) Polymerase 1 Activity. Int Arch Allergy Immunol. 2023; 184:447\u2013459.https:\/\/doi.org\/10.1159\/000527535.","DOI":"10.1159\/000527535"},{"key":"385_CR159","doi-asserted-by":"publisher","first-page":"2681","DOI":"10.1073\/pnas.1621508114","volume":"114","author":"T Kozaki","year":"2017","unstructured":"Kozaki T, Komano J, Kanbayashi D, Takahama M, Misawa T, Satoh T, et al. Mitochondrial damage elicits a TCDD-inducible poly(ADP-ribose) polymerase-mediated antiviral response. Proc Natl Acad Sci U S A. 2017;114:2681\u20136. https:\/\/doi.org\/10.1073\/pnas.1621508114.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"385_CR160","doi-asserted-by":"publisher","first-page":"113103","DOI":"10.1016\/j.celrep.2023.113103","volume":"42","author":"PA Desingu","year":"2023","unstructured":"Desingu PA, Mishra S, Dindi L, Srinivasan S, Rajmani RS, Ravi V, et al. PARP1 inhibition protects mice against Japanese encephalitis virus infection. Cell Rep. 2023;42:113103. https:\/\/doi.org\/10.1016\/j.celrep.2023.113103.","journal-title":"Cell Rep"},{"key":"385_CR161","doi-asserted-by":"publisher","unstructured":"Li L, Zhao H, Liu P, Li C, Quanquin N, Ji X, et al. PARP12 suppresses Zika virus infection through PARP-dependent degradation of NS1 and NS3 viral proteins. Sci Signal. 2018; 11:9332.https:\/\/doi.org\/10.1126\/scisignal.aas9332.","DOI":"10.1126\/scisignal.aas9332"},{"key":"385_CR162","doi-asserted-by":"publisher","first-page":"101808","DOI":"10.1016\/j.xpro.2022.101808","volume":"3","author":"F Wang","year":"2022","unstructured":"Wang F, Ma MT, Xu J, Liu H. Identification of phosphorylation site on PARP1 mediating its cytosolic translocation in virus-infected HeLa cells. STAR Protoc. 2022;3:101808. https:\/\/doi.org\/10.1016\/j.xpro.2022.101808.","journal-title":"STAR Protoc"},{"key":"385_CR163","doi-asserted-by":"publisher","unstructured":"Wang F, Zhao M, Chang B, Zhou Y, Wu X, Ma M, et al. Cytoplasmic PARP1 links the genome instability to the inhibition of antiviral immunity through PARylating cGAS. Mol Cell. 2022; 82:2032\u20132049 e2037.https:\/\/doi.org\/10.1016\/j.molcel.2022.03.034.","DOI":"10.1016\/j.molcel.2022.03.034"},{"key":"385_CR164","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1128\/JVI.05897-11","volume":"86","author":"Z Li","year":"2012","unstructured":"Li Z, Yamauchi Y, Kamakura M, Murayama T, Goshima F, Kimura H, et al. Herpes simplex virus requires poly(ADP-ribose) polymerase activity for efficient replication and induces extracellular signal-related kinase-dependent phosphorylation and ICP0-dependent nuclear localization of tankyrase 1. J Virol. 2012;86:492\u2013503. https:\/\/doi.org\/10.1128\/JVI.05897-11.","journal-title":"J Virol"},{"key":"385_CR165","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.3390\/v14092049","volume":"14","author":"W Zhang","year":"2022","unstructured":"Zhang W, Guo J, Chen Q. Role of PARP-1 in human cytomegalovirus infection and functional partners encoded by this virus. Viruses. 2022;14:2049. https:\/\/doi.org\/10.3390\/v14092049.","journal-title":"Viruses"},{"issue":"22","key":"385_CR166","doi-asserted-by":"publisher","first-page":"12092","DOI":"10.1093\/nar\/gkad936","volume":"51","author":"D Maestri","year":"2023","unstructured":"Maestri D, Napoletani G, Kossenkov A, Preston-Alp S, Caruso LB, Tempera I. The three-dimensional structure of the EBV genome plays a crucial role in regulating viral gene expression in EBVaGC. Nucleic Acids Res. 2023;51(22):12092\u2013110. https:\/\/doi.org\/10.1093\/nar\/gkad936.","journal-title":"Nucleic Acids Res"},{"key":"385_CR167","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/s41467-021-27894-1","volume":"13","author":"SM Morgan","year":"2022","unstructured":"Morgan SM, Tanizawa H, Caruso LB, Hulse M, Kossenkov A, Madzo J, et al. The three-dimensional structure of Epstein-Barr virus genome varies by latency type and is regulated by PARP1 enzymatic activity. Nat Commun. 2022;13:187. https:\/\/doi.org\/10.1038\/s41467-021-27894-1.","journal-title":"Nat Commun"},{"key":"385_CR168","doi-asserted-by":"publisher","unstructured":"Ohsaki E, Ueda K, Sakakibara S, Do E, Yada K, Yamanishi K. Poly(ADP-ribose) polymerase 1 binds to Kaposi's sarcoma-associated herpesvirus (KSHV) terminal repeat sequence and modulates KSHV replication in latency. J Virol. 2004; 78:9936\u20139946.https:\/\/doi.org\/10.1128\/JVI.78.18.9936-9946.2004.","DOI":"10.1128\/JVI.78.18.9936-9946.2004"},{"key":"385_CR169","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1107\/S2052252518013854","volume":"5","author":"WC Chung","year":"2018","unstructured":"Chung WC, Kim J, Kim BC, Kang HR, Son J, Ki H, et al. Structure-based mechanism of action of a viral poly(ADP-ribose) polymerase 1-interacting protein facilitating virus replication. IUCrJ. 2018;5:866\u201379. https:\/\/doi.org\/10.1107\/S2052252518013854.","journal-title":"IUCrJ"},{"key":"385_CR170","doi-asserted-by":"publisher","unstructured":"Nebenzahl-Sharon K, Sharf R, Amer J, Shalata H, Khoury-Haddad H, Sohn SY, et al. An Interaction with PARP-1 and Inhibition of Parylation Contribute to Attenuation of DNA Damage Signaling by the Adenovirus E4orf4 Protein. J Virol. 2019; 93:e02253\u201302218.https:\/\/doi.org\/10.1128\/JVI.02253-18.","DOI":"10.1128\/JVI.02253-18"},{"key":"385_CR171","doi-asserted-by":"publisher","unstructured":"Deng Z, Atanasiu C, Zhao K, Marmorstein R, Sbodio JI, Chi NW, et al. Inhibition of Epstein-Barr virus OriP function by tankyrase, a telomere-associated poly-ADP ribose polymerase that binds and modifies EBNA1. J Virol. 2005; 79:4640\u20134650.https:\/\/doi.org\/10.1128\/JVI.79.8.4640-4650.2005.","DOI":"10.1128\/JVI.79.8.4640-4650.2005"},{"key":"385_CR172","doi-asserted-by":"publisher","unstructured":"Lupey-Green LN, Moquin SA, Martin KA, McDevitt SM, Hulse M, Caruso LB, et al. PARP1 restricts Epstein Barr Virus lytic reactivation by binding the BZLF1 promoter. Virology. 2017; 507:220\u2013230.https:\/\/doi.org\/10.1016\/j.virol.2017.04.006.","DOI":"10.1016\/j.virol.2017.04.006"},{"key":"385_CR173","doi-asserted-by":"publisher","unstructured":"Kim C, Wang XD, Yu Y. PARP1 inhibitors trigger innate immunity via PARP1 trapping-induced DNA damage response. Elife. 2020; 9.https:\/\/doi.org\/10.7554\/eLife.60637.","DOI":"10.7554\/eLife.60637"},{"key":"385_CR174","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1158\/0008-5472.CAN-18-1003","volume":"79","author":"J Shen","year":"2019","unstructured":"Shen J, Zhao W, Ju Z, Wang L, Peng Y, Labrie M, et al. PARPi triggers the STING-dependent immune response and enhances the therapeutic efficacy of immune checkpoint blockade independent of BRCAness. Cancer Res. 2019;79:311\u20139. https:\/\/doi.org\/10.1158\/0008-5472.CAN-18-1003.","journal-title":"Cancer Res"},{"key":"385_CR175","doi-asserted-by":"publisher","first-page":"7882","DOI":"10.1038\/ncomms8882","volume":"6","author":"V Iansante","year":"2015","unstructured":"Iansante V, Choy PM, Fung SW, Liu Y, Chai JG, Dyson J, et al. PARP14 promotes the Warburg effect in hepatocellular carcinoma by inhibiting JNK1-dependent PKM2 phosphorylation and activation. Nat Commun. 2015;6:7882. https:\/\/doi.org\/10.1038\/ncomms8882.","journal-title":"Nat Commun"},{"key":"385_CR176","doi-asserted-by":"publisher","first-page":"17986","DOI":"10.1074\/jbc.RA120.015138","volume":"295","author":"CD Heer","year":"2020","unstructured":"Heer CD, Sanderson DJ, Voth LS, Alhammad YMO, Schmidt MS, Trammell SAJ, et al. Coronavirus infection and PARP expression dysregulate the NAD metabolome: an actionable component of innate immunity. J Biol Chem. 2020;295:17986\u201396. https:\/\/doi.org\/10.1074\/jbc.RA120.015138.","journal-title":"J Biol Chem"},{"key":"385_CR177","doi-asserted-by":"publisher","first-page":"118975","DOI":"10.1016\/j.lfs.2020.118975","volume":"267","author":"K Thapa","year":"2021","unstructured":"Thapa K, Khan H, Sharma U, Grewal AK, Singh TG. Poly (ADP-ribose) polymerase-1 as a promising drug target for neurodegenerative diseases. Life Sci. 2021;267:118975. https:\/\/doi.org\/10.1016\/j.lfs.2020.118975.","journal-title":"Life Sci"},{"key":"385_CR178","doi-asserted-by":"publisher","unstructured":"Motyl J, Wencel PL, Cieslik M, Strosznajder RP, Strosznajder JB. Alpha-synuclein alters differently gene expression of Sirts, PARPs and other stress response proteins: implications for neurodegenerative disorders. Mol Neurobiol. 2018; 55:727\u2013740.https:\/\/doi.org\/10.1007\/s12035-016-0317-1.","DOI":"10.1007\/s12035-016-0317-1"},{"key":"385_CR179","doi-asserted-by":"publisher","first-page":"156152","DOI":"10.1016\/j.phymed.2024.156152","volume":"135","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, Chen JC, Zheng JH, Cheng YZ, Weng WP, Zhong RL, et al. Pterosin B improves cognitive dysfunction by promoting microglia M1\/M2 polarization through inhibiting Klf5\/Parp14 pathway. Phytomedicine. 2024;135:156152. https:\/\/doi.org\/10.1016\/j.phymed.2024.156152.","journal-title":"Phytomedicine"},{"key":"385_CR180","doi-asserted-by":"publisher","unstructured":"Xu W, Wu Y, Mao R, Jia Y, Jiang H, Zhang F, et al. Poly(ADP-ribose) polymerase 1 orchestrates vascular smooth muscle cell homeostasis in arterial disease. Exp Mol Med. 2025.https:\/\/doi.org\/10.1038\/s12276-025-01501-5.","DOI":"10.1038\/s12276-025-01501-5"},{"key":"385_CR181","doi-asserted-by":"publisher","first-page":"155617","DOI":"10.1016\/j.phymed.2024.155617","volume":"129","author":"J Lin","year":"2024","unstructured":"Lin J, Wang X, Gu M, Chen Y, Xu J, VChau N, et al. Geniposide ameliorates atherosclerosis by restoring lipophagy via suppressing PARP1\/PI3K\/AKT signaling pathway. Phytomedicine. 2024;129:155617. https:\/\/doi.org\/10.1016\/j.phymed.2024.155617.","journal-title":"Phytomedicine"},{"key":"385_CR182","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1136\/annrheumdis-2012-202275","volume":"72","author":"A Distler","year":"2013","unstructured":"Distler A, Deloch L, Huang J, Dees C, Lin NY, Palumbo-Zerr K, et al. Inactivation of tankyrases reduces experimental fibrosis by inhibiting canonical Wnt signalling. Ann Rheum Dis. 2013;72:1575\u201380. https:\/\/doi.org\/10.1136\/annrheumdis-2012-202275.","journal-title":"Ann Rheum Dis"},{"key":"385_CR183","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.2174\/1389450117666160715152503","volume":"18","author":"TV Lakshmi","year":"2017","unstructured":"Lakshmi TV, Bale S, Khurana A, Godugu C. Tankyrase as a novel molecular target in cancer and fibrotic diseases. Curr Drug Targets. 2017;18:1214\u201324. https:\/\/doi.org\/10.2174\/1389450117666160715152503.","journal-title":"Curr Drug Targets"},{"key":"385_CR184","doi-asserted-by":"publisher","first-page":"116257","DOI":"10.1016\/j.taap.2022.116257","volume":"456","author":"VR Sunil","year":"2022","unstructured":"Sunil VR, Vayas KN, Radbel J, Abramova E, Gow A, Laskin JD, et al. Impaired energy metabolism and altered functional activity of alveolar type II epithelial cells following exposure of rats to nitrogen mustard. Toxicol Appl Pharmacol. 2022;456:116257. https:\/\/doi.org\/10.1016\/j.taap.2022.116257.","journal-title":"Toxicol Appl Pharmacol"},{"key":"385_CR185","doi-asserted-by":"publisher","first-page":"107612","DOI":"10.1016\/j.toxicon.2024.107612","volume":"239","author":"Q Lu","year":"2024","unstructured":"Lu Q, Wang N, Wen D, Guo P, Liu Y, Fu S, et al. Baicalin attenuates lipopolysaccharide-induced intestinal inflammatory injury via suppressing PARP1-mediated NF-\u03baB and NLRP3 signalling pathway. Toxicon. 2024;239:107612. https:\/\/doi.org\/10.1016\/j.toxicon.2024.107612.","journal-title":"Toxicon"},{"key":"385_CR186","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1074\/jbc.M110.157768","volume":"286","author":"P Mehrotra","year":"2011","unstructured":"Mehrotra P, Riley JP, Patel R, Li F, Voss L, Goenka S. PARP-14 functions as a transcriptional switch for Stat6-dependent gene activation. J Biol Chem. 2011;286:1767\u201376. https:\/\/doi.org\/10.1074\/jbc.M110.157768.","journal-title":"J Biol Chem"},{"key":"385_CR187","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1007\/s00018-022-04459-z","volume":"79","author":"K Fettucciari","year":"2022","unstructured":"Fettucciari K, Marguerie F, Fruganti A, Marchegiani A, Spaterna A, Brancorsini S, et al. Clostridioides difficile toxin B alone and with pro-inflammatory cytokines induces apoptosis in enteric glial cells by activating three different signalling pathways mediated by caspases, calpains and cathepsin B. Cell Mol Life Sci. 2022;79:442. https:\/\/doi.org\/10.1007\/s00018-022-04459-z.","journal-title":"Cell Mol Life Sci"},{"key":"385_CR188","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1111\/imm.12099","volume":"139","author":"MM Rosado","year":"2013","unstructured":"Rosado MM, Bennici E, Novelli F, Pioli C. Beyond DNA repair, the immunological role of PARP-1 and its siblings. Immunology. 2013;139:428\u201337. https:\/\/doi.org\/10.1111\/imm.12099.","journal-title":"Immunology"},{"key":"385_CR189","doi-asserted-by":"publisher","unstructured":"Kamboj A, Lu P, Cossoy MB, Stobart JL, Dolhun BA, Kauppinen TM, et al. Poly(ADP-ribose) polymerase 2 contributes to neuroinflammation and neurological dysfunction in mouse experimental autoimmune encephalomyelitis. J Neuroinflammation. 2013; 10:49.https:\/\/doi.org\/10.1186\/1742-2094-10-49.","DOI":"10.1186\/1742-2094-10-49"},{"key":"385_CR190","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.jhep.2016.08.024","volume":"66","author":"K Gariani","year":"2017","unstructured":"Gariani K, Ryu D, Menzies KJ, Yi HS, Stein S, Zhang H, et al. Inhibiting poly ADP-ribosylation increases fatty acid oxidation and protects against fatty liver disease. J Hepatol. 2017;66:132\u201341. https:\/\/doi.org\/10.1016\/j.jhep.2016.08.024.","journal-title":"J Hepatol"},{"key":"385_CR191","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.cmet.2011.03.013","volume":"13","author":"P Bai","year":"2011","unstructured":"Bai P, Canto C, Brunyanszki A, Huber A, Szanto M, Cen Y, et al. PARP-2 regulates SIRT1 expression and whole-body energy expenditure. Cell Metab. 2011;13:450\u201360. https:\/\/doi.org\/10.1016\/j.cmet.2011.03.013.","journal-title":"Cell Metab"},{"key":"385_CR192","doi-asserted-by":"publisher","unstructured":"Marton J, Peter M, Balogh G, Bodi B, Vida A, Szanto M, et al. Poly(ADP-ribose) polymerase-2 is a lipid-modulated modulator of muscular lipid homeostasis. Biochim Biophys Acta Mol Cell Biol Lipids. 2018; 1863:1399\u20131412.https:\/\/doi.org\/10.1016\/j.bbalip.2018.07.013.","DOI":"10.1016\/j.bbalip.2018.07.013"},{"key":"385_CR193","doi-asserted-by":"publisher","first-page":"e7430","DOI":"10.1371\/journal.pone.0007430","volume":"4","author":"CP Hans","year":"2009","unstructured":"Hans CP, Feng Y, Naura AS, Zerfaoui M, Rezk BM, Xia H, et al. Protective effects of PARP-1 knockout on dyslipidemia-induced autonomic and vascular dysfunction in ApoE mice: effects on eNOS and oxidative stress. PLoS ONE. 2009;4:e7430. https:\/\/doi.org\/10.1371\/journal.pone.0007430.","journal-title":"PLoS ONE"},{"key":"385_CR194","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1124\/jpet.108.145938","volume":"329","author":"CP Hans","year":"2009","unstructured":"Hans CP, Zerfaoui M, Naura AS, Troxclair D, Strong JP, Matrougui K, et al. Thieno[2,3-c]isoquinolin-5-one, a potent poly(ADP-ribose) polymerase inhibitor, promotes atherosclerotic plaque regression in high-fat diet-fed apolipoprotein E-deficient mice: effects on inflammatory markers and lipid content. J Pharmacol Exp Ther. 2009;329:150\u20138. https:\/\/doi.org\/10.1124\/jpet.108.145938.","journal-title":"J Pharmacol Exp Ther"},{"key":"385_CR195","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.jhep.2016.10.023","volume":"66","author":"P Mukhopadhyay","year":"2017","unstructured":"Mukhopadhyay P, Horvath B, Rajesh M, Varga ZV, Gariani K, Ryu D, et al. PARP inhibition protects against alcoholic and non-alcoholic steatohepatitis. J Hepatol. 2017;66:589\u2013600. https:\/\/doi.org\/10.1016\/j.jhep.2016.10.023.","journal-title":"J Hepatol"},{"key":"385_CR196","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.fct.2017.02.039","volume":"103","author":"Y Choi","year":"2017","unstructured":"Choi Y, Abdelmegeed MA, Song BJ. Diet high in fructose promotes liver steatosis and hepatocyte apoptosis in C57BL\/6J female mice: role of disturbed lipid homeostasis and increased oxidative stress. Food Chem Toxicol. 2017;103:111\u201321. https:\/\/doi.org\/10.1016\/j.fct.2017.02.039.","journal-title":"Food Chem Toxicol"},{"key":"385_CR197","doi-asserted-by":"publisher","unstructured":"Oumouna-Benachour K, Hans CP, Suzuki Y, Naura A, Datta R, Belmadani S, et al. Poly(ADP-ribose) polymerase inhibition reduces atherosclerotic plaque size and promotes factors of plaque stability in apolipoprotein E-deficient mice: effects on macrophage recruitment, nuclear factor-kappaB nuclear translocation, and foam cell death. Circulation. 2007; 115:2442\u20132450.https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.106.668756.","DOI":"10.1161\/CIRCULATIONAHA.106.668756"},{"key":"385_CR198","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1042\/BST20130187","volume":"42","author":"N Curtin","year":"2014","unstructured":"Curtin N. PARP inhibitors for anticancer therapy. Biochem Soc Trans. 2014;42:82\u20138. https:\/\/doi.org\/10.1042\/BST20130187.","journal-title":"Biochem Soc Trans"},{"key":"385_CR199","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.cell.2017.03.034","volume":"169","author":"KY Lin","year":"2017","unstructured":"Lin KY, Kraus WL. PARP inhibitors for cancer therapy. Cell. 2017;169:183. https:\/\/doi.org\/10.1016\/j.cell.2017.03.034.","journal-title":"Cell"},{"key":"385_CR200","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s13578-020-00390-7","volume":"10","author":"M Patel","year":"2020","unstructured":"Patel M, Nowsheen S, Maraboyina S, Xia F. The role of poly(ADP-ribose) polymerase inhibitors in the treatment of cancer and methods to overcome resistance: a review. Cell Biosci. 2020;10:35. https:\/\/doi.org\/10.1186\/s13578-020-00390-7.","journal-title":"Cell Biosci"},{"key":"385_CR201","first-page":"550","volume":"18","author":"KN Moore","year":"2020","unstructured":"Moore KN, Pothuri B, Monk B, Coleman RL. PARP inhibition as frontline therapy in ovarian cancer. Clin Adv Hematol Oncol. 2020;18:550\u20136.","journal-title":"Clin Adv Hematol Oncol"},{"key":"385_CR202","doi-asserted-by":"publisher","unstructured":"Loibl S, O'Shaughnessy J, Untch M, Sikov WM, Rugo HS, McKee MD, et al. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. Lancet Oncol. 2018; 19:497\u2013509.https:\/\/doi.org\/10.1016\/S1470-2045(18)30111-6.","DOI":"10.1016\/S1470-2045(18)30111-6"},{"issue":"10","key":"385_CR203","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1007\/s40265-021-01541-x","volume":"81","author":"A Lee","year":"2021","unstructured":"Lee A. Fuzuloparib: first approval. Drugs. 2021;81(10):1221\u20136. https:\/\/doi.org\/10.1007\/s40265-021-01541-x.","journal-title":"Drugs"},{"key":"385_CR204","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1007\/s40265-021-01552-8","volume":"81","author":"A Markham","year":"2021","unstructured":"Markham A. Pamiparib: first approval. Drugs. 2021;81:1343\u20138. https:\/\/doi.org\/10.1007\/s40265-021-01552-8.","journal-title":"Drugs"},{"key":"385_CR205","doi-asserted-by":"publisher","unstructured":"Lee A. Senaparib: First Approval. Drugs. 2025.https:\/\/doi.org\/10.1007\/s40265-025-02200-1.","DOI":"10.1007\/s40265-025-02200-1"},{"key":"385_CR206","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.bcp.2012.03.018","volume":"84","author":"M De Vos","year":"2012","unstructured":"De Vos M, Schreiber V, Dantzer F. The diverse roles and clinical relevance of PARPs in DNA damage repair: current state of the art. Biochem Pharmacol. 2012;84:137\u201346. https:\/\/doi.org\/10.1016\/j.bcp.2012.03.018.","journal-title":"Biochem Pharmacol"},{"key":"385_CR207","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1038\/nrm2851","volume":"11","author":"ME Moynahan","year":"2010","unstructured":"Moynahan ME, Jasin M. Mitotic homologous recombination maintains genomic stability and suppresses tumorigenesis. Nat Rev Mol Cell Biol. 2010;11:196\u2013207. https:\/\/doi.org\/10.1038\/nrm2851.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"385_CR208","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.cmet.2011.03.004","volume":"13","author":"P Bai","year":"2011","unstructured":"Bai P, Canto C, Oudart H, Brunyanszki A, Cen Y, Thomas C, et al. PARP-1 inhibition increases mitochondrial metabolism through SIRT1 activation. Cell Metab. 2011;13:461\u20138. https:\/\/doi.org\/10.1016\/j.cmet.2011.03.004.","journal-title":"Cell Metab"},{"key":"385_CR209","doi-asserted-by":"publisher","unstructured":"Hassa PO, Hottiger MO. The diverse biological roles of mammalian PARPS, a small but powerful family of poly-ADP-ribose polymerases. Front Biosci. 2008; 13:3046\u20133082.https:\/\/doi.org\/10.2741\/2909.","DOI":"10.2741\/2909"},{"key":"385_CR210","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1101\/gad.183509.111","volume":"26","author":"X Luo","year":"2012","unstructured":"Luo X, Kraus WL. On PAR with PARP: cellular stress signaling through poly(ADP-ribose) and PARP-1. Genes Dev. 2012;26:417\u201332. https:\/\/doi.org\/10.1101\/gad.183509.111.","journal-title":"Genes Dev"},{"key":"385_CR211","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/nrd1718","volume":"4","author":"P Jagtap","year":"2005","unstructured":"Jagtap P, Szabo C. Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors. Nat Rev Drug Discov. 2005;4:421\u201340. https:\/\/doi.org\/10.1038\/nrd1718.","journal-title":"Nat Rev Drug Discov"},{"key":"385_CR212","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.4049\/jimmunol.174.4.2288","volume":"174","author":"TM Kauppinen","year":"2005","unstructured":"Kauppinen TM, Swanson RA. Poly(ADP-ribose) polymerase-1 promotes microglial activation, proliferation, and matrix metalloproteinase-9-mediated neuron death. J Immunol. 2005;174:2288\u201396. https:\/\/doi.org\/10.4049\/jimmunol.174.4.2288.","journal-title":"J Immunol"},{"key":"385_CR213","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.bcp.2018.10.005","volume":"162","author":"A Tapodi","year":"2019","unstructured":"Tapodi A, Bognar Z, Szabo C, Gallyas F, Sumegi B, Hocsak E. PARP inhibition induces Akt-mediated cytoprotective effects through the formation of a mitochondria-targeted phospho-ATM-NEMO-Akt-mTOR signalosome. Biochem Pharmacol. 2019;162:98\u2013108. https:\/\/doi.org\/10.1016\/j.bcp.2018.10.005.","journal-title":"Biochem Pharmacol"},{"key":"385_CR214","doi-asserted-by":"publisher","unstructured":"Miyamoto S, Murphy AN, Brown JH. Akt mediates mitochondrial protection in cardiomyocytes through phosphorylation of mitochondrial hexokinase-II. Cell Death Differ. 2008;15:521\u20139. https:\/\/doi.org\/10.1038\/sj.cdd.4402285.","DOI":"10.1038\/sj.cdd.4402285"},{"key":"385_CR215","doi-asserted-by":"publisher","unstructured":"Gallyas F, Jr., Sumegi B. Mitochondrial Protection by PARP Inhibition. Int J Mol Sci. 2020; 21:2767.https:\/\/doi.org\/10.3390\/ijms21082767.","DOI":"10.3390\/ijms21082767"},{"key":"385_CR216","doi-asserted-by":"publisher","unstructured":"D'Ambrosio C, Erriquez J, Capellero S, Cignetto S, Alvaro M, Ciamporcero E, et al. Cancer Cells Haploinsufficient for ATM Are Sensitized to PARP Inhibitors by MET Inhibition. Int J Mol Sci. 2022; 23:5770.https:\/\/doi.org\/10.3390\/ijms23105770.","DOI":"10.3390\/ijms23105770"},{"key":"385_CR217","doi-asserted-by":"publisher","first-page":"8412","DOI":"10.3390\/ijms23158412","volume":"23","author":"D Kim","year":"2022","unstructured":"Kim D, Nam HJ. PARP inhibitors: clinical limitations and recent attempts to overcome them. Int J Mol Sci. 2022;23:8412. https:\/\/doi.org\/10.3390\/ijms23158412.","journal-title":"Int J Mol Sci"},{"key":"385_CR218","doi-asserted-by":"publisher","unstructured":"Luo L, Keyomarsi K. PARP inhibitors as single agents and in combination therapy: the most promising treatment strategies in clinical trials for BRCA-mutant ovarian and triple-negative breast cancers. Expert Opin Investig Drugs. 2022; 31:607\u2013631.https:\/\/doi.org\/10.1080\/13543784.2022.2067527.","DOI":"10.1080\/13543784.2022.2067527"},{"key":"385_CR219","doi-asserted-by":"publisher","unstructured":"Singh H, Singh AK, Kumar A, Kumar P. Patents on PARP-1 Inhibitors for the Management of Cancer from 2017\u20132023. Recent Pat Anticancer Drug Discov. 2024; 1:1\u201313.https:\/\/doi.org\/10.2174\/0115748928315021240603073902.","DOI":"10.2174\/0115748928315021240603073902"},{"key":"385_CR220","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1158\/2159-8290.CD-18-1218","volume":"9","author":"C Pantelidou","year":"2019","unstructured":"Pantelidou C, Sonzogni O, De Oliveria Taveira M, Mehta AK, Kothari A, Wang D, et al. PARP inhibitor efficacy depends on CD8(+) T-cell recruitment via intratumoral STING pathway activation in BRCA-deficient models of triple-negative breast cancer. Cancer Discov. 2019;9:722\u201337. https:\/\/doi.org\/10.1158\/2159-8290.CD-18-1218.","journal-title":"Cancer Discov"},{"key":"385_CR221","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1158\/2159-8290.CD-18-1020","volume":"9","author":"T Sen","year":"2019","unstructured":"Sen T, Rodriguez BL, Chen L, Corte CMD, Morikawa N, Fujimoto J, et al. Targeting DNA damage response promotes antitumor immunity through STING-mediated T-cell activation in small cell lung cancer. Cancer Discov. 2019;9:646\u201361. https:\/\/doi.org\/10.1158\/2159-8290.CD-18-1020.","journal-title":"Cancer Discov"},{"key":"385_CR222","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1016\/j.chembiol.2016.12.003","volume":"23","author":"CL Doig","year":"2016","unstructured":"Doig CL, Lavery GG. PARP inhibitors: staying on target? Cell Chem Biol. 2016;23:1442\u20133. https:\/\/doi.org\/10.1016\/j.chembiol.2016.12.003.","journal-title":"Cell Chem Biol"},{"key":"385_CR223","doi-asserted-by":"publisher","unstructured":"Knezevic CE, Wright G, Rix LLR, Kim W, Kuenzi BM, Luo Y, et al. Proteome-wide Profiling of Clinical PARP Inhibitors Reveals Compound-Specific Secondary Targets. Cell Chem Biol. 2016; 23:1490\u20131503.https:\/\/doi.org\/10.1016\/j.chembiol.2016.10.011.","DOI":"10.1016\/j.chembiol.2016.10.011"},{"key":"385_CR224","doi-asserted-by":"publisher","first-page":"3726","DOI":"10.1038\/s41467-020-17127-2","volume":"11","author":"H Kim","year":"2020","unstructured":"Kim H, Xu H, George E, Hallberg D, Kumar S, Jagannathan V, et al. Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models. Nat Commun. 2020;11:3726. https:\/\/doi.org\/10.1038\/s41467-020-17127-2.","journal-title":"Nat Commun"},{"key":"385_CR225","doi-asserted-by":"publisher","first-page":"3485","DOI":"10.1200\/JCO.2015.62.2290","volume":"33","author":"S Mueller","year":"2015","unstructured":"Mueller S, Haas-Kogan DA. WEE1 kinase as a target for cancer therapy. J Clin Oncol. 2015;33:3485\u20137. https:\/\/doi.org\/10.1200\/JCO.2015.62.2290.","journal-title":"J Clin Oncol"},{"key":"385_CR226","doi-asserted-by":"publisher","first-page":"5085","DOI":"10.1158\/1078-0432.CCR-14-1038","volume":"20","author":"D Karnak","year":"2014","unstructured":"Karnak D, Engelke CG, Parsels LA, Kausar T, Wei D, Robertson JR, et al. Combined inhibition of Wee1 and PARP1\/2 for radiosensitization in pancreatic cancer. Clin Cancer Res. 2014;20:5085\u201396. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-1038.","journal-title":"Clin Cancer Res"},{"key":"385_CR227","doi-asserted-by":"publisher","unstructured":"Mateo J, Lord CJ, Serra V, Tutt A, Balmana J, Castroviejo-Bermejo M, et al. A decade of clinical development of PARP inhibitors in perspective. Ann Oncol. 2019;30:1437\u201347. https:\/\/doi.org\/10.1093\/annonc\/mdz192.","DOI":"10.1093\/annonc\/mdz192"},{"key":"385_CR228","doi-asserted-by":"publisher","unstructured":"Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, et al. Oral poly(ADP-1551 ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and 1552 advanced breast cancer: a proof-of-concept trial. Lancet. 2010;376:235\u201344. https:\/\/doi.org\/10.1016\/S0140-6736(10)60892-6.","DOI":"10.1016\/S0140-6736(10)60892-6"},{"key":"385_CR229","doi-asserted-by":"publisher","unstructured":"Domchek SM, Postel-Vinay S, Im SA, Park YH, Delord JP, Italiano A, et al. Olaparib and 1555 durvalumab in patients with germline BRCA-mutated metastatic breast cancer 1556 (MEDIOLA): an open-label, multicentre, phase 1\/2, basket study. Lancet Oncol. 2020;21:1155\u201364. https:\/\/doi.org\/10.1016\/S1470-2045(20)30324-7.","DOI":"10.1016\/S1470-2045(20)30324-7"},{"key":"385_CR230","doi-asserted-by":"publisher","unstructured":"Maiorano BA, Catalano M, Maiorano MFP, Signori A, Loizzi V, Cormio G, et al. 1559 Hematological toxicity of parp inhibitors in solid tumors: a systematic review and safety 1560 meta-analysis. Cancer Metastasis Rev. 2025;44:65. https:\/\/doi.org\/10.1007\/s10555-025-156110283-1.","DOI":"10.1007\/s10555-025-156110283-1"},{"key":"385_CR231","doi-asserted-by":"publisher","unstructured":"Moore DC, Ringley JT, Patel J. Rucaparib: A Poly(ADP-Ribose) Polymerase Inhibitor for 1563 BRCA-Mutated Relapsed Ovarian Cancer. J Pharm Pract. 2019;32:219\u201324. https:\/\/doi.org\/10.1177\/0897190017743131.","DOI":"10.1177\/0897190017743131"},{"key":"385_CR232","doi-asserted-by":"publisher","unstructured":"Cetin B, Wabl CA, Gumusay O. The DNA damaging revolution. Crit Rev Oncol Hematol. 2020;156:103117. https:\/\/doi.org\/10.1016\/j.critrevonc.2020.103117.","DOI":"10.1016\/j.critrevonc.2020.103117"},{"key":"385_CR233","doi-asserted-by":"publisher","unstructured":"Kristeleit R, Leary A, Oaknin A, Redondo A, George A, Chui S, et al. PARP inhibition with 1568 rucaparib alone followed by combination with atezolizumab: Phase Ib COUPLET clinical 1569 study in advanced gynaecological and triple-negative breast cancers. Br J Cancer. 2024;131:820\u201331. https:\/\/doi.org\/10.1038\/s41416-024-02776-7.","DOI":"10.1038\/s41416-024-02776-7"},{"key":"385_CR234","doi-asserted-by":"publisher","unstructured":"Loehr A, Hussain A, Patnaik A, Bryce AH, Castellano D, Font A, et al. Emergence of BRCA 1572 Reversion Mutations in Patients with Metastatic Castration-resistant Prostate Cancer After 1573 Treatment with Rucaparib. Eur Urol. 2023;83:200\u20139. https:\/\/doi.org\/10.1016\/j.eururo.2022.09.010.","DOI":"10.1016\/j.eururo.2022.09.010"},{"key":"385_CR235","doi-asserted-by":"publisher","unstructured":"Wang L, Wang Q, Xu Y, Cui M, Han L. Advances in the Treatment of Ovarian Cancer Using 1519 PARP Inhibitors and the Underlying Mechanism of Resistance. Curr Drug Targets. 2020;21:167\u201378. https:\/\/doi.org\/10.2174\/1389450120666190925123507.","DOI":"10.2174\/1389450120666190925123507"},{"key":"385_CR236","doi-asserted-by":"publisher","unstructured":"Li N, Zhu J, Yin R, Wang J, Pan L, Kong B, et al. Treatment With Niraparib Maintenance 1522 Therapy in Patients With Newly Diagnosed Advanced Ovarian Cancer: A Phase 3 1523 Randomized Clinical Trial. JAMA Oncol. 2023;9:1230\u20137. https:\/\/doi.org\/10.1001\/jamaoncol.2023.2283.","DOI":"10.1001\/jamaoncol.2023.2283"},{"key":"385_CR237","doi-asserted-by":"publisher","unstructured":"Chi KN, Fleshner N, Chiuri VE, Van Bruwaene S, Hafron J, McNeel DG, et al. Niraparib with 1576 Abiraterone Acetate and Prednisone for Metastatic Castration-Resistant Prostate Cancer: 1577 Phase II QUEST Study Results. Oncologist. 2023;28:e309\u201312. https:\/\/doi.org\/10.1093\/oncolo\/oyad008.","DOI":"10.1093\/oncolo\/oyad008"},{"key":"385_CR238","doi-asserted-by":"publisher","unstructured":"Roberts HN, Maurice-Dror C, Chi KN. Combination niraparib and abiraterone for HRR-1580 altered metastatic castration-resistant prostate cancer. Future Oncol. 2025;21:201\u201311. https:\/\/doi.org\/10.1080\/14796694.2024.2442900.","DOI":"10.1080\/14796694.2024.2442900"},{"key":"385_CR239","doi-asserted-by":"publisher","unstructured":"Hobbs EA, Litton JK, Yap TA. Development of the PARP inhibitor talazoparib for the 1583 treatment of advanced BRCA1 and BRCA2 mutated breast cancer. Expert Opin 1584 Pharmacother. 2021;22:1825\u201337. https:\/\/doi.org\/10.1080\/14656566.2021.1952181.","DOI":"10.1080\/14656566.2021.1952181"},{"key":"385_CR240","doi-asserted-by":"publisher","unstructured":"Mittra A, Coyne G, Zlott J, Kummar S, Meehan R, Rubinstein L, et al. Pharmacodynamic 1586 effects of the PARP inhibitor talazoparib (MDV3800, BMN 673) in patients with BRCA-mutated advanced solid tumors. Cancer Chemother Pharmacol. 2024;93:177\u201389. https:\/\/doi.org\/10.1007\/s00280-023-04600-0.","DOI":"10.1007\/s00280-023-04600-0"},{"key":"385_CR241","doi-asserted-by":"publisher","unstructured":"Mo W, Liu Q, Lin CC, Dai H, Peng Y, Liang Y, et al. mTOR Inhibitors Suppress Homologous 1590 Recombination Repair and Synergize with PARP Inhibitors via Regulating SUV39H1 in 1591 BRCA-Proficient Triple-Negative Breast Cancer. Clin Cancer Res. 2016;22:1699\u2013712. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-1772.","DOI":"10.1158\/1078-0432.CCR-15-1772"},{"key":"385_CR242","doi-asserted-by":"publisher","unstructured":"Thakur A, Chu YH, Rao NV, Mathew J, Grewal AS, Prabakaran P, et al. Leveraging a 1594 rationally designed veliparib-based anilide eliciting anti-leukemic effects for the design of 1595 pH-responsive polymer nanoformulation. Eur J Med Chem. 2024;273:116507. https:\/\/doi.org\/10.1016\/j.ejmech.2024.116507.","DOI":"10.1016\/j.ejmech.2024.116507"},{"key":"385_CR243","doi-asserted-by":"publisher","unstructured":"Cai SX, Ma N, Wang X, Guo M, Jiang Y, Tian YE. The Discovery of a Potent PARP1 Inhibitor 1545 Senaparib. Mol Cancer Ther. 2025;24:47\u201355. https:\/\/doi.org\/10.1158\/1535-7163.MCT-23-15460625.","DOI":"10.1158\/1535-7163.MCT-23-15460625"},{"key":"385_CR244","doi-asserted-by":"publisher","unstructured":"Banerjee S, Moore KN, Colombo N, Scambia G, Kim BG, Oaknin A, et al. Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation 1510 (SOLO1\/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, 1511 phase 3 trial. Lancet Oncol. 2021;22:1721\u201331. https:\/\/doi.org\/10.1016\/S1470-15122045(21)00531-3.","DOI":"10.1016\/S1470-15122045(21)00531-3"},{"key":"385_CR245","doi-asserted-by":"publisher","unstructured":"Cook SA, Tinker AV. PARP Inhibitors and the Evolving Landscape of Ovarian Cancer 1514 Management: A Review. BioDrugs. 2019;33:255\u201373. https:\/\/doi.org\/10.1007\/s40259-1515019-00347-4.","DOI":"10.1007\/s40259-1515019-00347-4"},{"key":"385_CR246","doi-asserted-by":"publisher","unstructured":"O'Malley DM, Krivak TC, Kabil N, Munley J, Moore KN. PARP Inhibitors in Ovarian Cancer: 1517 A Review. Target Oncol. 2023;18:471\u2013503. https:\/\/doi.org\/10.1007\/s11523-023-00970-w.","DOI":"10.1007\/s11523-023-00970-w"},{"key":"385_CR247","doi-asserted-by":"publisher","unstructured":"Monk BJ, Parkinson C, Lim MC, O'Malley DM, Oaknin A, Wilson MK, et al. A Randomized, 1526 Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients 1527 With Newly Diagnosed Ovarian Cancer (ATHENA-MONO\/GOG-3020\/ENGOT-ov45). J 1528 Clin Oncol. 2022;40:3952\u201364. https:\/\/doi.org\/10.1200\/JCO.22.01003.","DOI":"10.1200\/JCO.22.01003"},{"key":"385_CR248","doi-asserted-by":"publisher","unstructured":"Sharma N, Bhati A, Aggarwal S, Shah K, Dewangan HK. PARP Pioneers: Using BRCA1\/2 1530 Mutation-targeted Inhibition to Revolutionize Breast Cancer Treatment. Curr Pharm Des. 1531 2025;31:663\u201373. https:\/\/doi.org\/10.2174\/0113816128322894241004051814.","DOI":"10.2174\/0113816128322894241004051814"},{"key":"385_CR249","doi-asserted-by":"publisher","unstructured":"Saad F, Armstrong AJ, Shore N, George DJ, Oya M, Sugimoto M, et al. Olaparib Monotherapy 1533 or in Combination with Abiraterone for the Treatment of Patients with Metastatic 1534 Castration-Resistant Prostate Cancer (mCRPC) and a BRCA Mutation. Target Oncol. 2025;20:445\u201366. https:\/\/doi.org\/10.1007\/s11523-025-01146-4.","DOI":"10.1007\/s11523-025-01146-4"},{"key":"385_CR250","doi-asserted-by":"publisher","unstructured":"Chi KN, Sandhu S, Smith MR, Attard G, Saad M, Olmos D, et al. Niraparib plus abiraterone 1537 acetate with prednisone in patients with metastatic castration-resistant prostate cancer and 1538 homologous recombination repair gene alterations: second interim analysis of the 1539 randomized phase III MAGNITUDE trial. Ann Oncol. 2023;34:772\u201382. https:\/\/doi.org\/10.1016\/j.annonc.2023.06.009.","DOI":"10.1016\/j.annonc.2023.06.009"},{"key":"385_CR251","doi-asserted-by":"publisher","unstructured":"Golan T, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall MJ, et al. Maintenance Olaparib 1542 for Germline BRCA-Mutated Metastatic Pancreatic Cancer. N Engl J Med. 2019;381:317\u201327. https:\/\/doi.org\/10.1056\/NEJMoa1903387.","DOI":"10.1056\/NEJMoa1903387"},{"key":"385_CR252","doi-asserted-by":"publisher","unstructured":"Murai K, Kodama T, Hikita H, Shimoda A, Fukuoka M, Fukutomi K, et al. Inhibition of 1598 nonhomologous end joining-mediated DNA repair enhances anti-HBV CRISPR therapy. 1599 Hepatol Commun. 2022;6:2474\u201387. https:\/\/doi.org\/10.1002\/hep4.2014.","DOI":"10.1002\/hep4.2014"},{"key":"385_CR253","doi-asserted-by":"publisher","unstructured":"Stone NE, Jaramillo SA, Jones AN, Vazquez AJ, Martz M, Versluis LM, et al. Stenoparib, an Inhibitor of Cellular Poly(ADP-Ribose) Polymerase, Blocks Replication of the SARS-CoV-2 and HCoV-NL63 Human Coronaviruses In Vitro. mBio. 2021; 12:e03495\u201303420.https:\/\/doi.org\/10.1128\/mBio.03495-20.","DOI":"10.1128\/mBio.03495-20"},{"key":"385_CR254","doi-asserted-by":"publisher","unstructured":"Ge Y, Tian T, Huang S, Wan F, Li J, Li S, et al. An integrative drug repositioning framework 1613 discovered a potential therapeutic agent targeting COVID-19. Signal Transduct Target Ther. 2021;6:165. https:\/\/doi.org\/10.1038\/s41392-021-00568-6.","DOI":"10.1038\/s41392-021-00568-6"},{"key":"385_CR255","doi-asserted-by":"publisher","unstructured":"Zhao D, Xu W, Zhang X, Wang X, Ge Y, Yuan E, et al. Understanding the phase separation 1616 characteristics of nucleocapsid protein provides a new therapeutic opportunity against 1617 SARS-CoV-2. Protein Cell. 2021;12:734\u201340. https:\/\/doi.org\/10.1007\/s13238-021-00832-1618z.","DOI":"10.1007\/s13238-021-00832-1618z"},{"key":"385_CR256","doi-asserted-by":"publisher","unstructured":"Tibebe H, Marquez D, McGraw A, Gagliardi S, Sullivan C, Hillmer G, et al. Targeting Latent 1635 HIV Reservoirs: Effectiveness of Combination Therapy with HDAC and PARP Inhibitors. 1636 Viruses. 2025;17. https:\/\/doi.org\/10.3390\/v17030400.","DOI":"10.3390\/v17030400"},{"key":"385_CR257","doi-asserted-by":"publisher","unstructured":"Rom S, Reichenbach NL, Dykstra H, Persidsky Y. The dual action of poly(ADP-ribose) 1644 polymerase -1 (PARP-1) inhibition in HIV-1 infection: HIV-1 LTR inhibition and 1645 diminution in Rho GTPase activity. Front Microbiol. 2015;6:878. https:\/\/doi.org\/10.3389\/fmicb.2015.00878.","DOI":"10.3389\/fmicb.2015.00878"},{"key":"385_CR258","doi-asserted-by":"publisher","unstructured":"Arena A, Gilardini Montani MS, Romeo MA, Benedetti R, Gaeta A, Cirone M. DNA damage 1631 triggers an interplay between wtp53 and c-Myc affecting lymphoma cell proliferation and 1632 Kaposi sarcoma herpesvirus replication. Biochim Biophys Acta Mol Cell Res. 2022;1869:119168. https:\/\/doi.org\/10.1016\/j.bbamcr.2021.119168.","DOI":"10.1016\/j.bbamcr.2021.119168"},{"key":"385_CR259","doi-asserted-by":"publisher","unstructured":"Liu W, Ren X, Wang Q, Zhang Y, Du J. Pharmacological inhibition of poly (ADP-ribose) 1610 polymerase by olaparib ameliorates influenza-virus-induced pneumonia in mice. Eur J Clin 1611 Microbiol Infect Dis. 2021;40:159\u201367. https:\/\/doi.org\/10.1007\/s10096-020-04020-5.","DOI":"10.1007\/s10096-020-04020-5"},{"key":"385_CR260","doi-asserted-by":"publisher","unstructured":"Tomao F, Santangelo G, Musacchio L, Di Donato V, Fischetti M, Giancotti A, et al. Targeting 1648 cervical cancer: Is there a role for poly (ADP-ribose) polymerase inhibition? J Cell Physiol. 2020;235:5050\u20138. https:\/\/doi.org\/10.1002\/jcp.29440.","DOI":"10.1002\/jcp.29440"},{"key":"385_CR261","doi-asserted-by":"publisher","unstructured":"Elayapillai SP, Dogra S, Lausen J, Parker M, Kennedy A, Benbrook DM, et al. ATR inhibition 1651 increases reliance on PARP-mediated DNA repair revealing an improved therapeutic 1652 strategy for cervical cancer. Gynecol Oncol. 2024;191:182\u201393. https:\/\/doi.org\/10.1016\/j.ygyno.2024.10.009.","DOI":"10.1016\/j.ygyno.2024.10.009"},{"key":"385_CR262","doi-asserted-by":"publisher","unstructured":"Moutafi M, Economopoulou P, Rimm D, Psyrri A. PARP inhibitors in head and neck cancer: 1655 Molecular mechanisms, preclinical and clinical data. Oral Oncol. 2021;117:105292. https:\/\/doi.org\/10.1016\/j.oraloncology.2021.105292.","DOI":"10.1016\/j.oraloncology.2021.105292"},{"key":"385_CR263","doi-asserted-by":"publisher","unstructured":"Mann M, Singh VP, Kumar L. Cervical cancer: a tale from HPV infection to PARP inhibitors. 1605 Genes Dis. 2023;10:1445\u201356. https:\/\/doi.org\/10.1016\/j.gendis.2022.09.014.","DOI":"10.1016\/j.gendis.2022.09.014"},{"key":"385_CR264","doi-asserted-by":"publisher","unstructured":"Citro S, Ghiani L, Doni M, Miccolo C, Tagliabue M, Ansarin M, et al. HPV-mediated PARP1 1607 regulation and drug sensitization in head and neck cancer. Oral Oncol. 2025;165:107307. https:\/\/doi.org\/10.1016\/j.oraloncology.2025.107307.","DOI":"10.1016\/j.oraloncology.2025.107307"},{"key":"385_CR265","doi-asserted-by":"publisher","unstructured":"Dorna D, Kleszcz R, Paluszczak J. Triple Combinations of Histone Lysine Demethylase 1620 Inhibitors with PARP1 Inhibitor-Olaparib and Cisplatin Lead to Enhanced Cytotoxic 1621 Effects in Head and Neck Cancer Cells. Biomedicines. 2024;12. https:\/\/doi.org\/10.3390\/biomedicines12061359.","DOI":"10.3390\/biomedicines12061359"},{"key":"385_CR266","doi-asserted-by":"publisher","unstructured":"M IJ, Mei X, Scutigliani EM, Rodermond HM, van Bochove GGW, Krawczyk PM, et al. 1624 Addition of PARP1-inhibition enhances chemoradiotherapy and thermoradiotherapy when 1625 treating cervical cancer in an in vivo mouse model. Int J Hyperthermia. 2025;42:2450514. https:\/\/doi.org\/10.1080\/02656736.2025.2450514.","DOI":"10.1080\/02656736.2025.2450514"},{"key":"385_CR267","doi-asserted-by":"publisher","unstructured":"M IJ, van Bochove GGW, Whitton D, Winiarczyk R, Honhoff C, Rodermond H, et al. PARP1-1628 Inhibition Sensitizes Cervical Cancer Cell Lines for Chemoradiation and Thermoradiation. 1629 Cancers (Basel). 2021;13. https:\/\/doi.org\/10.3390\/cancers13092092.","DOI":"10.3390\/cancers13092092"},{"key":"385_CR268","doi-asserted-by":"publisher","unstructured":"Karlberg H, Tan YJ, Mirazimi A. Crimean-Congo haemorrhagic fever replication interplays 1638 with regulation mechanisms of apoptosis. J Gen Virol. 2015;96:538\u201346. https:\/\/doi.org\/10.1099\/jgv.0.000011.","DOI":"10.1099\/jgv.0.000011"},{"key":"385_CR269","doi-asserted-by":"publisher","unstructured":"Ahsan NA, Sampey GC, Lepene B, Akpamagbo Y, Barclay RA, Iordanskiy S, et al. Presence 1641 of Viral RNA and Proteins in Exosomes from Cellular Clones Resistant to Rift Valley Fever 1642 Virus Infection. Front Microbiol. 2016;7:139. https:\/\/doi.org\/10.3389\/fmicb.2016.00139.","DOI":"10.3389\/fmicb.2016.00139"},{"key":"385_CR270","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.biochi.2023.03.009","volume":"211","author":"S Singla","year":"2023","unstructured":"Singla S, Kumar V, Jena G. 3-aminobenzamide protects against colitis associated diabetes mellitus in male BALB\/c mice: role of PARP-1, NLRP3, SIRT-1, AMPK. Biochimie. 2023;211:96\u2013109. https:\/\/doi.org\/10.1016\/j.biochi.2023.03.009.","journal-title":"Biochimie"},{"key":"385_CR271","doi-asserted-by":"publisher","unstructured":"Santinelli-Pestana DV, Aikawa E, Singh SA, Aikawa M. PARPs and ADP-Ribosylation in Chronic Inflammation: A Focus on Macrophages. Pathogens. 2023; 12.https:\/\/doi.org\/10.3390\/pathogens12070964.","DOI":"10.3390\/pathogens12070964"},{"key":"385_CR272","doi-asserted-by":"publisher","unstructured":"Zhou J, Du T, Wang X, Yao H, Deng J, Li Y, et al. Discovery of Quinazoline-2,4(1H,3H)-dione Derivatives Containing a Piperizinone Moiety as Potent PARP-1\/2 Inhibitors horizontal line Design, Synthesis, In Vivo Antitumor Activity, and X-ray Crystal Structure Analysis. J Med Chem. 2023; 66:14095\u201314115.https:\/\/doi.org\/10.1021\/acs.jmedchem.3c01152.","DOI":"10.1021\/acs.jmedchem.3c01152"},{"key":"385_CR273","doi-asserted-by":"publisher","first-page":"2725","DOI":"10.1158\/1078-0432.CCR-22-3715","volume":"29","author":"YN Kim","year":"2023","unstructured":"Kim YN, Shim Y, Seo J, Choi Z, Lee YJ, Shin S, et al. Investigation of PARP inhibitor resistance based on serially collected circulating tumor DNA in patients with BRCA-mutated ovarian cancer. Clin Cancer Res. 2023;29:2725\u201334. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-3715.","journal-title":"Clin Cancer Res"},{"key":"385_CR274","doi-asserted-by":"publisher","first-page":"e2400140","DOI":"10.1002\/advs.202400140","volume":"11","author":"Z Zhan","year":"2024","unstructured":"Zhan Z, Zhang J, Liang H, Wang C, Hong L, Liu W. Kat6a condensates impair PARP1 trapping of PARP inhibitors in ovarian cancer. Adv Sci. 2024;11:e2400140. https:\/\/doi.org\/10.1002\/advs.202400140.","journal-title":"Adv Sci"},{"key":"385_CR275","doi-asserted-by":"publisher","first-page":"114234","DOI":"10.1016\/j.celrep.2024.114234","volume":"43","author":"PB Kanev","year":"2024","unstructured":"Kanev PB, Varhoshkova S, Georgieva I, Lukarska M, Kirova D, Danovski G, et al. A unified mechanism for PARP inhibitor-induced PARP1 chromatin retention at DNA damage sites in living cells. Cell Rep. 2024;43:114234. https:\/\/doi.org\/10.1016\/j.celrep.2024.114234.","journal-title":"Cell Rep"},{"key":"385_CR276","doi-asserted-by":"publisher","first-page":"555","DOI":"10.21873\/anticanres.15513","volume":"42","author":"SH Moon","year":"2022","unstructured":"Moon SH, Park NS, Noh MH, Kim YS, Cheong SH, Hur DY. Olaparib-induced apoptosis through EBNA1-ATR-p38 MAPK signaling pathway in Epstein-Barr virus-positive gastric cancer cells. Anticancer Res. 2022;42:555\u201363. https:\/\/doi.org\/10.21873\/anticanres.15513.","journal-title":"Anticancer Res"},{"key":"385_CR277","doi-asserted-by":"publisher","first-page":"5445","DOI":"10.1158\/1078-0432.CCR-23-3785","volume":"30","author":"J Chou","year":"2024","unstructured":"Chou J, Robinson TM, Egusa EA, Lodha R, Zhang M, Badura M, et al. Synthetic lethal targeting of CDK12-deficient prostate cancer with PARP inhibitors. Clin Cancer Res. 2024;30:5445\u201358. https:\/\/doi.org\/10.1158\/1078-0432.CCR-23-3785.","journal-title":"Clin Cancer Res"},{"key":"385_CR278","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.2174\/1389450122666210120142746","volume":"22","author":"J Rajawat","year":"2021","unstructured":"Rajawat J, Chandra A. Role of poly(ADP-ribose) polymerase (PARP1) in viral infection and its implication in SARS-CoV-2 pathogenesis. Curr Drug Targets. 2021;22:1477\u201384. https:\/\/doi.org\/10.2174\/1389450122666210120142746.","journal-title":"Curr Drug Targets"},{"key":"385_CR279","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/NEJMoa1910962","volume":"381","author":"A Gonzalez-Martin","year":"2019","unstructured":"Gonzalez-Martin A, Pothuri B, Vergote I, DePont Christensen R, Graybill W, Mirza MR, et al. Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2019;381:2391\u2013402. https:\/\/doi.org\/10.1056\/NEJMoa1910962.","journal-title":"N Engl J Med"},{"key":"385_CR280","doi-asserted-by":"publisher","first-page":"3022","DOI":"10.1038\/s41467-022-30568-1","volume":"13","author":"Q Wang","year":"2022","unstructured":"Wang Q, Bergholz JS, Ding L, Lin Z, Kabraji SK, Hughes ME, et al. STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancer. Nat Commun. 2022;13:3022. https:\/\/doi.org\/10.1038\/s41467-022-30568-1.","journal-title":"Nat Commun"},{"key":"385_CR281","doi-asserted-by":"publisher","unstructured":"Jiao S, Xia W, Yamaguchi H, Wei Y, Chen MK, Hsu JM, et al. PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression. Clin Cancer Res. 2017; 23:3711\u20133720.https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-3215.","DOI":"10.1158\/1078-0432.CCR-16-3215"},{"key":"385_CR282","doi-asserted-by":"publisher","first-page":"4536","DOI":"10.1158\/1078-0432.CCR-22-0568","volume":"28","author":"V Serra","year":"2022","unstructured":"Serra V, Wang AT, Castroviejo-Bermejo M, Polanska UM, Palafox M, Herencia-Ropero A, et al. Identification of a molecularly-defined subset of breast and ovarian cancer models that respond to WEE1 or ATR inhibition, overcoming PARP inhibitor resistance. Clin Cancer Res. 2022;28:4536\u201350. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-0568.","journal-title":"Clin Cancer Res"},{"key":"385_CR283","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1056\/NEJMoa1802905","volume":"379","author":"JK Litton","year":"2018","unstructured":"Litton JK, Rugo HS, Ettl J, Hurvitz SA, Goncalves A, Lee KH, et al. Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med. 2018;379:753\u201363. https:\/\/doi.org\/10.1056\/NEJMoa1802905.","journal-title":"N Engl J Med"},{"key":"385_CR284","doi-asserted-by":"publisher","unstructured":"Menissier de Murcia J, Ricoul M, Tartier L, Niedergang C, Huber A, Dantzer F, et al. Functional interaction between PARP-1 and PARP-2 in chromosome stability and embryonic development in mouse. EMBO J. 2003; 22:2255\u20132263.https:\/\/doi.org\/10.1093\/emboj\/cdg206.","DOI":"10.1093\/emboj\/cdg206"},{"key":"385_CR285","doi-asserted-by":"publisher","first-page":"102629","DOI":"10.1016\/j.eclinm.2024.102629","volume":"72","author":"X Wu","year":"2024","unstructured":"Wu X, Zhu J, Yin R, Yang J, Liu J, Wang J, et al. Niraparib maintenance therapy using an individualised starting dose in patients with platinum-sensitive recurrent ovarian cancer (NORA): final overall survival analysis of a phase 3 randomised, placebo-controlled trial. EClinicalMedicine. 2024;72:102629. https:\/\/doi.org\/10.1016\/j.eclinm.2024.102629.","journal-title":"EClinicalMedicine"},{"key":"385_CR286","doi-asserted-by":"publisher","first-page":"114157","DOI":"10.1016\/j.ejca.2024.114157","volume":"208","author":"C Vulsteke","year":"2024","unstructured":"Vulsteke C, Chambers SK, Perez MJR, Chan JK, Raaschou-Jensen N, Zhuo Y, et al. Tolerability of the niraparib individualized starting dose in the PRIMA\/ENGOT-OV26\/GOG-3012 trial of niraparib first-line maintenance therapy. Eur J Cancer. 2024;208:114157. https:\/\/doi.org\/10.1016\/j.ejca.2024.114157.","journal-title":"Eur J Cancer"},{"key":"385_CR287","doi-asserted-by":"publisher","first-page":"e122","DOI":"10.1016\/S2352-3026(20)30360-4","volume":"8","author":"PM Morice","year":"2021","unstructured":"Morice PM, Leary A, Dolladille C, Chretien B, Poulain L, Gonzalez-Martin A, et al. Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database. Lancet Haematol. 2021;8:e122\u201334. https:\/\/doi.org\/10.1016\/S2352-3026(20)30360-4.","journal-title":"Lancet Haematol"},{"key":"385_CR288","doi-asserted-by":"publisher","first-page":"7308897","DOI":"10.1155\/2021\/7308897","volume":"2021","author":"D Kovacs","year":"2021","unstructured":"Kovacs D, Vantus VB, Vamos E, Kalman N, Schicho R, Gallyas F, et al. Olaparib: a clinically applied PARP inhibitor protects from experimental Crohn\u2019s disease and maintains barrier integrity by improving bioenergetics through rescuing glycolysis in colonic epithelial cells. Oxid Med Cell Longev. 2021;2021:7308897. https:\/\/doi.org\/10.1155\/2021\/7308897.","journal-title":"Oxid Med Cell Longev"},{"key":"385_CR289","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-025-04336-z","author":"SA Jasim","year":"2025","unstructured":"Jasim SA, Gupta J, Uthirapathy S, R R, Kazmi SW, Rizaev JA, et al. A comprehensive review of immunotherapy in gastrointestinal tumors with a focus on the role of combination therapy with PARP inhibitors. Naunyn Schmiedebergs Arch Pharmacol. 2025. https:\/\/doi.org\/10.1007\/s00210-025-04336-z.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"385_CR290","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1080\/14740338.2024.2390640","volume":"24","author":"C Yang","year":"2025","unstructured":"Yang C, Song X, Sun H, Chen X, Liu C, Chen M. Cardiovascular adverse events associated with PARP inhibitors for ovarian cancer: a real world study (RWS) with Bayesian disproportional analysis based on the FDA adverse event reporting system (FAERS). Expert Opin Drug Saf. 2025;24:1039\u201346. https:\/\/doi.org\/10.1080\/14740338.2024.2390640.","journal-title":"Expert Opin Drug Saf"},{"key":"385_CR291","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.tjog.2024.05.020","volume":"63","author":"N Adrianto","year":"2024","unstructured":"Adrianto N, Mangkuliguna G, Tandiono EJ, Sibarani CNR. Efficacy and safety of rucaparib in patients with recurrent high-grade ovarian carcinoma: a systematic review and meta-analysis. Taiwan J Obstet Gynecol. 2024;63:601\u20139. https:\/\/doi.org\/10.1016\/j.tjog.2024.05.020.","journal-title":"Taiwan J Obstet Gynecol"},{"key":"385_CR292","doi-asserted-by":"publisher","unstructured":"Stanislawiak-Rudowicz J, Karbownik A, Szkutnik-Fiedler D, Otto F, Grabowski T, Wolc A, et al. Bidirectional pharmacokinetic drug interactions between olaparib and metformin. Cancer Chemother Pharmacol. 2024; 93:79\u201388.https:\/\/doi.org\/10.1007\/s00280-023-04591-y.","DOI":"10.1007\/s00280-023-04591-y"},{"key":"385_CR293","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1080\/00365513.2018.1472803","volume":"78","author":"TM El-Gammacy","year":"2018","unstructured":"El-Gammacy TM, Shinkar DM, Mohamed NR, Al-Halag AR. Serum cystatin C as an early predictor of acute kidney injury in preterm neonates with respiratory distress syndrome. Scand J Clin Lab Invest. 2018;78:352\u20137. https:\/\/doi.org\/10.1080\/00365513.2018.1472803.","journal-title":"Scand J Clin Lab Invest"},{"key":"385_CR294","doi-asserted-by":"publisher","first-page":"4724","DOI":"10.1158\/1078-0432.CCR-22-0301","volume":"28","author":"G Illuzzi","year":"2022","unstructured":"Illuzzi G, Staniszewska AD, Gill SJ, Pike A, McWilliams L, Critchlow SE, et al. Preclinical characterization of AZD5305, a next-generation, highly selective PARP1 inhibitor and trapper. Clin Cancer Res. 2022;28:4724\u201336. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-0301.","journal-title":"Clin Cancer Res"},{"key":"385_CR295","doi-asserted-by":"publisher","first-page":"107193","DOI":"10.1016\/j.ejps.2025.107193","volume":"212","author":"N Peng","year":"2025","unstructured":"Peng N, Chen D, Yang M, Zeng C, Li W. PARP inhibitors for HRR-deficient metastatic castration-resistant prostate cancer: mechanisms and clinical strategies. Eur J Pharm Sci. 2025;212:107193. https:\/\/doi.org\/10.1016\/j.ejps.2025.107193.","journal-title":"Eur J Pharm Sci"},{"key":"385_CR296","doi-asserted-by":"publisher","unstructured":"Thorsell AG, Ekblad T, Karlberg T, Low M, Pinto AF, Tresaugues L, et al. Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors. J Med Chem. 2017; 60:1262\u20131271.https:\/\/doi.org\/10.1021\/acs.jmedchem.6b00990.","DOI":"10.1021\/acs.jmedchem.6b00990"},{"key":"385_CR297","doi-asserted-by":"publisher","first-page":"115329","DOI":"10.1016\/j.bcp.2022.115329","volume":"206","author":"G Li","year":"2022","unstructured":"Li G, Lin SS, Yu ZL, Wu XH, Liu JW, Tu GH, et al. A PARP1 PROTAC as a novel strategy against PARP inhibitor resistance via promotion of ferroptosis in p53-positive breast cancer. Biochem Pharmacol. 2022;206:115329. https:\/\/doi.org\/10.1016\/j.bcp.2022.115329.","journal-title":"Biochem Pharmacol"},{"key":"385_CR298","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1097\/GCO.0000000000000517","volume":"31","author":"KE McCann","year":"2019","unstructured":"McCann KE. Poly-ADP-ribosyl-polymerase inhibitor resistance mechanisms and their therapeutic implications. Curr Opin Obstet Gynecol. 2019;31:12\u20137. https:\/\/doi.org\/10.1097\/GCO.0000000000000517.","journal-title":"Curr Opin Obstet Gynecol"},{"issue":"1","key":"385_CR299","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s13073-018-0612-8","volume":"10","author":"P Francica","year":"2018","unstructured":"Francica P, Rottenberg S. Mechanisms of PARP inhibitor resistance in cancer and insights into the DNA damage response. Genome Med. 2018;10(1):101. https:\/\/doi.org\/10.1186\/s13073-018-0612-8.","journal-title":"Genome Med"},{"key":"385_CR300","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/s41388-024-03227-6","volume":"44","author":"A Jain","year":"2025","unstructured":"Jain A, Barge A, Parris CN. Combination strategies with PARP inhibitors in BRCA-mutated triple-negative breast cancer: overcoming resistance mechanisms. Oncogene. 2025;44:193\u2013207. https:\/\/doi.org\/10.1038\/s41388-024-03227-6.","journal-title":"Oncogene"},{"key":"385_CR301","doi-asserted-by":"publisher","first-page":"915","DOI":"10.20892\/j.issn.2095-3941.2023.0260","volume":"20","author":"Q Tang","year":"2024","unstructured":"Tang Q, Wang X, Wang H, Zhong L, Zou D. Advances in ATM, ATR, WEE1, and CHK1\/2 inhibitors in the treatment of PARP inhibitor-resistant ovarian cancer. Cancer Biol Med. 2024;20:915\u201321. https:\/\/doi.org\/10.20892\/j.issn.2095-3941.2023.0260.","journal-title":"Cancer Biol Med"},{"key":"385_CR302","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.3892\/or.2015.3873","volume":"33","author":"F Baldan","year":"2015","unstructured":"Baldan F, Mio C, Lavarone E, Di Loreto C, Puglisi F, Damante G, et al. Epigenetic bivalent marking is permissive to the synergy of HDAC and PARP inhibitors on TXNIP expression in breast cancer cells. Oncol Rep. 2015;33:2199\u2013206. https:\/\/doi.org\/10.3892\/or.2015.3873.","journal-title":"Oncol Rep"},{"key":"385_CR303","doi-asserted-by":"publisher","first-page":"202","DOI":"10.3389\/fphar.2012.00202","volume":"3","author":"A Lovato","year":"2012","unstructured":"Lovato A, Panasci L, Witcher M. Is there an epigenetic component underlying the resistance of triple-negative breast cancers to PARP inhibitors? Front Pharmacol. 2012;3:202. https:\/\/doi.org\/10.3389\/fphar.2012.00202.","journal-title":"Front Pharmacol"},{"key":"385_CR304","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s10549-022-06780-4","volume":"197","author":"T Gupta","year":"2023","unstructured":"Gupta T, Vinayak S, Telli M. Emerging strategies: PARP inhibitors in combination with immune checkpoint blockade in BRCA1 and BRCA2 mutation-associated and triple-negative breast cancer. Breast Cancer Res Treat. 2023;197:51\u20136. https:\/\/doi.org\/10.1007\/s10549-022-06780-4.","journal-title":"Breast Cancer Res Treat"},{"key":"385_CR305","doi-asserted-by":"publisher","first-page":"724620","DOI":"10.3389\/fonc.2021.724620","volume":"11","author":"J Ni","year":"2021","unstructured":"Ni J, Cheng X, Zhou R, Zhao Q, Xu X, Guo W, et al. Adverse events as a potential clinical marker of antitumor efficacy in ovarian cancer patients treated with poly ADP-ribose polymerase inhibitor. Front Oncol. 2021;11:724620. https:\/\/doi.org\/10.3389\/fonc.2021.724620.","journal-title":"Front Oncol"},{"key":"385_CR306","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1124\/jpet.114.222448","volume":"353","author":"Y Shen","year":"2015","unstructured":"Shen Y, Aoyagi-Scharber M, Wang B. Trapping poly(ADP-ribose) polymerase. J Pharmacol Exp Ther. 2015;353:446\u201357. https:\/\/doi.org\/10.1124\/jpet.114.222448.","journal-title":"J Pharmacol Exp Ther"},{"key":"385_CR307","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.semcdb.2016.12.009","volume":"63","author":"A Vida","year":"2017","unstructured":"Vida A, Marton J, Miko E, Bai P. Metabolic roles of poly(ADP-ribose) polymerases. Semin Cell Dev Biol. 2017;63:135\u201343. https:\/\/doi.org\/10.1016\/j.semcdb.2016.12.009.","journal-title":"Semin Cell Dev Biol"},{"key":"385_CR308","doi-asserted-by":"publisher","first-page":"206","DOI":"10.2174\/1871520618666181109164645","volume":"19","author":"N Li","year":"2019","unstructured":"Li N, Wang Y, Deng W, Lin SH. Poly (ADP-ribose) polymerases (PARPs) and PARP inhibitor-targeted therapeutics. Anticancer Agents Med Chem. 2019;19:206\u201312. https:\/\/doi.org\/10.2174\/1871520618666181109164645.","journal-title":"Anticancer Agents Med Chem"},{"key":"385_CR309","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.2174\/0929867054864778","volume":"12","author":"EC Woon","year":"2005","unstructured":"Woon EC, Threadgill MD. Poly(ADP-ribose)polymerase inhibition - where now? Curr Med Chem. 2005;12:2373\u201392. https:\/\/doi.org\/10.2174\/0929867054864778.","journal-title":"Curr Med Chem"}],"container-title":["Molecular Biomedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43556-025-00385-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43556-025-00385-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43556-025-00385-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T01:05:13Z","timestamp":1767056713000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s43556-025-00385-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,29]]},"references-count":309,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["385"],"URL":"https:\/\/doi.org\/10.1186\/s43556-025-00385-1","relation":{},"ISSN":["2662-8651"],"issn-type":[{"value":"2662-8651","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,29]]},"assertion":[{"value":"23 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors state that there is no conflict of interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"152"}}